

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number
WO 2004/077060 A2

(51) International Patent Classification⁷: G01N 33/574

(21) International Application Number:

PCT/CA2004/000280

(22) International Filing Date: 26 February 2004 (26.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/451,382 27 February 2003 (27.02.2003) US

(71) Applicant (for all designated States except US): MOUNT SINAI HOSPITAL [CA/CA]; 600 University Avenue, Room 970, Toronto, Ontario M5G 1X5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DIAMANDIS, Eleftherios, P. [CA/CA]; 44 Gerrard Street West, Suite 1504, Toronto, Ontario M5G 2K2 (CA). PETRAKI, Constantina, D. [GR/GR]; Department of Pathology, Evangelismos Hospital, Phedriadon 109, GR-113 64 Athens (GR).

(74) Agent: KURDYDYK, Linda; McCarthy Tetrault, 66 Wellington Street West, Suite 4700, P.O. Box 48, Toronto Dominion Bank Tower, Toronto Dominion Centre, Toronto, Ontario M5K 1E6 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/077060 A2

(54) Title: ASSAY FOR DETECTION OF RENAL CELL CARCINOMA

(57) Abstract: Methods for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting kallikrein polypeptides, or polynucleotides encoding the polypeptides in a sample from the subject. The kallikrein polypeptides include kallikrein 5, kallirekin 6, kallikrein 10, and kallikrein 11.

TITLE: Assay for Detection of Renal Cell Carcinoma**FIELD OF THE INVENTION**

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating renal cell carcinoma.

5 BACKGROUND OF THE INVENTION

Kallikreins are a subgroup of secreted serine proteases, encoded by highly conserved and tightly clustered multigene families in humans, rats and mice. The human kallikrein gene family resides on chromosome 19q13.4 and is comprised of 15 members, whose genes are designated as *KLK1* to *KLK15* and the corresponding proteins as hK1 to hK15 (Yousef GM, Diamandis EP., *Endocr Rev* .2001;22:184-204); 10 Yousef GM, Chang A, Scorilas A, et al., *Biochem Biophys Res Commun*. 2000;276:125-133; Diamandis EP, Yousef GM, Clements J, et al. *Clin Chem* .2000;46:1855-1858). Kallikreins are expressed in a wide variety of tissues and are found in many biological fluids (e.g. cerebrospinal fluid, serum, seminal plasma, milk, etc.) where they are predicted to process specific substrates. Kallikreins may participate in cascade reactions similar to those involved in digestion, fibrinolysis, coagulation, wound healing and apoptosis (Yousef GM, 15 Diamandis EP., *Endocr Rev* .2001;22:184-204). Many kallikreins have been found to be differentially expressed in endocrine-related malignancies (Diamandis EP, Yousef GM, *Expert Rev. Mol. Diagn* .2001;1:182-190), including prostate (Barry MJ. Clinical practice, *N Engl J Med* .2001;344:1373-1377; Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al., *Crit Rev Clin Lab Sci* .1998;35:275-368; and Yousef GM, Scorilas A, Jung K, et al., *J Biol Chem* .2001;276:53-61), ovarian(Kim H, Scorilas A, Katsaros D, et 20 al., *Br J Cancer*, 2001;84:643-650; Anisowicz A, Sotiropoulou G, Stenman, et al., *Mol Med* .1996;2:624-636; Tanimoto H, Underwood LJ, Shigemasa K, et al., *Cancer* .1999;86:2074-2082; Magklara A, Scorilas A, Katsaros D, et al., *Clin Cancer Res* .2001;7:806-811; Yousef GM, Kyriakopoulou LG, Scorilas A, et al., *Cancer Res* .2001;61:7811-7818; Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118), breast (Yousef GM, Magklara A, Chang A, et al., *Cancer Res* .2001;61:3425-25 3431; Yousef GM, Chang A, Diamandis EP; *J Biol Chem* .2000;275:11891-11898; and Yousef GM, Magklara A, Diamandis EP, *Genomics* .2000;69:331-341), and testicular cancer (Luo LY, Rajpert-De Meyts ER, Jung K, et al.,2001;85:220-224). In addition, many kallikrein genes examined thus far are under steroid 30 hormone regulation, implicating a role for kallikreins in endocrine-related tissues (Yousef GM, Diamandis EP., *Endocr Rev*., 2001;22:184-204). Furthermore, hK6, hK10 and hK11 have been recently identified as novel serological ovarian cancer biomarkers (Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118 Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P., *Clin Biochem*. 2000;33:579-583, and Diamandis EP, Okui A, Mitsui S, et al., *Cancer Res* .2002;62:295-300).

SUMMARY OF THE INVENTION

The present invention seeks to overcome the drawbacks inherent in the prior art and provide 35 sensitive and accurate methods for the detection of renal cell carcinoma. It has been found that one or more kallikrein polypeptides wherein the kallikrein polypeptides are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and polynucleotides encoding the polypeptides, have particular application in the detection of renal cell carcinoma. Thus, the kallikrein markers constitute biomarkers for the diagnosis, monitoring, progression, treatment, and prognosis of renal cell carcinoma, and they may be used as biomarkers before

surgery or after relapse.

In accordance with the methods of the invention, the presence of levels of kallikrein markers in a sample can be assessed, for example by detecting the presence in the sample of (a) polypeptides or polypeptide fragments corresponding to the markers; (b) metabolites which are produced directly or 5 indirectly by polypeptides corresponding to the markers; (c) transcribed nucleic acids or fragments thereof having at least a portion with which the markers are substantially identical; and/or (c) transcribed nucleic acids or fragments thereof, wherein the nucleic acids hybridize with the markers.

In an embodiment, the invention provides a method for detecting one or more kallikrein polypeptides wherein the kallikrein polypeptides are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 10 associated with renal cell carcinoma in a patient comprising:

- (a) obtaining a sample from a patient;
- (b) detecting or identifying in the sample one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 15 associated with renal cell carcinoma; and

(c) comparing the detected amounts with amounts detected for a standard.

The term "detect" or "detecting" includes assaying, assessing, imaging or otherwise establishing the presence or absence of the target kallikrein polypeptides or polynucleotides encoding the polypeptides, subunits thereof, or combinations of reagent bound targets, and the like, or assaying for, imaging, ascertaining, establishing, or otherwise determining one or more factual characteristics of renal cell 20 carcinoma, metastasis, stage, or similar conditions. The term encompasses diagnostic, prognostic, and monitoring applications. The kallikrein markers can be detected individually, sequentially, or simultaneously.

According to a method involving one or more kallikrein polypeptides the levels in the sample of one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, 25 kallikrein 10, and kallikrein 11 associated with renal cell carcinoma, are compared with the normal levels of the kallikrein polypeptides, in samples of the same type obtained from controls (e.g. samples from individuals not afflicted with renal cell carcinoma). Significantly different levels in the sample of the kallikrein polypeptides relative to the normal levels in a control is indicative of renal cell carcinoma.

In an embodiment, the invention provides a method for diagnosing and monitoring renal cell 30 carcinoma in a subject comprising detecting in a sample from the subject one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma. The kallikrein markers can be detected using antibodies that bind to the kallikrein markers or parts thereof.

Thus, the invention provides a method of assessing whether a patient is afflicted with or has a pre- 35 disposition for renal cell carcinoma, the method comprising comparing:

- (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and

5 (b) normal levels of the kallikrein polypeptides, in samples of the same type obtained from control patients not afflicted with renal cell carcinoma, wherein significantly different levels of the kallikrein polypeptides, relative to the corresponding normal levels of the kallikrein polypeptides, is an indication that the patient is afflicted with renal cell carcinoma.

In an embodiment of a method of assessing whether a patient is afflicted with renal cell carcinoma (e.g. screening, detection of a recurrence, reflex testing), the method comprises comparing:

10 (a) levels of one or more, preferably 2 or more, kallikrein polypeptides in a sample from the patient, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and

(b) normal levels of the kallikrein polypeptides, in a control non-renal cell carcinoma sample.

15 A significant difference between the levels of the kallikrein polypeptides in the patient sample and the normal levels is an indication that the patient is afflicted with renal cell carcinoma. In an embodiment, the levels of kallikrein markers are significantly higher and are indicative of tumors of high grade, advanced stage disease, and/or lower survival.

The invention further relates to a method of assessing the efficacy of a therapy for inhibiting renal cell carcinoma in a patient. This method comprises comparing:

20 (a) levels of one or more kallikrein polypeptides in a sample from the patient obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and

(b) levels of the kallikrein polypeptides in a second sample obtained from the patient following therapy.

25 A significant difference between the levels of the kallikrein polypeptides in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting renal cell carcinoma.

The "therapy" may be any therapy for treating renal cell carcinoma including but not limited to chemotherapy, immunotherapy, gene therapy, radiation therapy, and surgical removal of tissue. Therefore, the method can be used to evaluate a patient before, during, and after therapy, for example, to evaluate the reduction in tumor burden.

30 In an aspect, the invention provides a method for monitoring the progression of renal cell carcinoma in a patient, the method comprising:

(a) detecting in a patient sample at a first time point, one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and

35 (b) repeating step (a) at a subsequent point in time; and

(c) comparing the levels detected in (a) and (b), and therefrom monitoring the progression of renal cell carcinoma in the patient.

In another aspect, the invention provides a method for assessing the aggressiveness or indolence of renal cell carcinoma (e.g. staging), the method comprising comparing:

- (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels of the kallikrein polypeptides in a control sample.

5 A significant difference between the levels in the sample and the normal levels is an indication that the cancer is aggressive or indolent.

The invention provides a method for determining whether renal cell carcinoma has metastasized or is likely to metastasize in the future, the method comprising comparing:

- 10 (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels (or non-metastatic levels) of the kallikrein polypeptides in a control sample.

A significant difference between the levels in the patient sample and the normal levels is an indication that the cancer has metastasized or is likely to metastasize in the future.

15 The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, and a method of selecting an agent for inhibiting renal cell carcinoma in a patient.

The invention further provides a method of inhibiting renal cell carcinoma in a patient comprising:

- 20 (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing levels of one or more kallikrein polypeptides, in each of the aliquots, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma;
- (d) administering to the patient at least one of the test agents which alters the levels of the kallikrein polypeptides in the aliquot containing that test agent, relative to other test agents.

25 The invention also contemplates a method of assessing the renal cell carcinoma carcinogenic potential of a test compound comprising:

- 30 (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and
- (b) comparing levels of kallikrein polypeptides in each of the aliquots, wherein the polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the kallikrein polypeptides in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses renal cell carcinoma carcinogenic potential.

35 In embodiments of the methods of the invention, two, three, or four kallikrein polypeptides are employed. In preferred embodiments, the kallikrein polypeptides comprise kallikrein 6; kallikrein 6 and kallikrein 10; kallikrein 6 and kallikrein 11; kallikrein 6, kallikrein 10, and kallikrein 11; or kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. In a particular embodiment, the kallikrein polypeptides are selected from the group consisting of kallikrein 6, kallikrein 10, and kallikrein 11.

Other methods of the invention employ one or more polynucleotides capable of hybridizing to polynucleotides encoding kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma. Methods for detecting polynucleotides encoding kallikrein polypeptides can be used to monitor renal cell carcinoma by detecting 5 the nucleic acids.

Thus, the present invention relates to a method for diagnosing and monitoring renal cell carcinoma in a sample from a subject comprising isolating nucleic acids, preferably mRNA, from the sample; and detecting polynucleotides encoding kallikrein polypeptides in the sample, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The presence of different 10 levels of polynucleotides encoding the kallikrein polypeptides, in the sample compared to a standard or control is indicative of disease, disease stage, and/or prognosis, e.g. progression-free and overall survival.

In an embodiment, the invention provides methods for determining the presence or absence of renal cell carcinoma in a subject comprising (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein polypeptides wherein the kallikrein 15 polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of renal cell carcinoma in the subject. Within certain embodiments, mRNA is detected via polymerase chain reaction using, for example oligonucleotide primers that hybridize to polynucleotides encoding kallikrein polypeptides, or complements of such nucleic acids. 20 Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing oligonucleotide probes that hybridize to polynucleotides encoding kallikrein polypeptides, or complements of such nucleic acids.

When using mRNA detection, the method may be carried out by combining isolated mRNA with reagents to convert to cDNA according to standard methods; treating the converted cDNA with amplification 25 reaction reagents (such as cDNA PCR reaction reagents) in a container along with an appropriate mixture of nucleic acid primers; reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of polynucleotides encoding kallikrein polypeptides in the sample. For mRNA the analyzing step may be accomplished using Northern Blot analysis to detect the presence of polynucleotides encoding kallikrein polypeptides. The analysis step may be further 30 accomplished by quantitatively detecting the presence of polynucleotides encoding kallikrein polypeptides in the amplification product, and comparing the quantity of markers detected against a panel of expected values for the known presence or absence of the markers in normal and malignant tissue derived using similar primers.

In embodiments of the invention, one, two, three or four polynucleotides encoding kallikrein 35 polypeptides are employed. In preferred embodiments, the polynucleotides encode kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and kallikrein 6, kallikrein 10 and kallikrein 11.

The invention also provides a diagnostic composition comprising kallikrein polypeptides, or polynucleotides encoding the polypeptides, or agents that bind to the polypeptides or nucleic acids.

In an embodiment, the composition comprises probes that specifically hybridize to polynucleotides

encoding kallikrein polypeptides, or fragments thereof. In another embodiment a composition is provided comprising specific primer pairs capable of amplifying polynucleotides encoding kallikrein polypeptides, using polymerase chain reaction methodologies. In a still further embodiment, the composition comprises agents that bind to kallikrein polypeptides (e.g. antibodies) or fragments thereof. Probes, primers, and agents 5 can be labeled with detectable substances.

In an aspect the invention provides an *in vivo* method comprising administering to a subject agents that have been constructed to target kallikrein polypeptides.

The invention therefore contemplates an *in vivo* method comprising administering to a mammal 10 imaging agents that carry labels for imaging and that bind to kallikrein polypeptides, and then imaging the mammal.

Still further the invention relates to therapeutic applications for renal cell carcinoma employing kallikrein polypeptides and polynucleotides encoding the polypeptides, and/or agents identified using methods of the invention.

The invention also includes kits for carrying out methods of the invention. In an embodiment, the 15 kit is for assessing whether a patient is afflicted with renal cell carcinoma and it comprises reagents for assessing one or more kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

In another aspect the invention relates to a kit for assessing the suitability of each of a plurality of 20 test compounds for inhibiting renal cell carcinoma in a patient. The kit comprises reagents for assessing kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The kit may also comprise a plurality of test agents or compounds.

The invention contemplates a kit for assessing the presence of renal cell carcinoma cells, wherein 25 the kit comprises antibodies specific for selected markers, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

Additionally the invention provides a kit for assessing the renal cell carcinoma carcinogenic potential of a test compound. The kit comprises renal cell carcinoma cells and reagents for assessing kallikrein markers, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

30 In an aspect the invention provides a method of treating a patient afflicted with renal cell carcinoma comprising providing to cells of a patient antisense oligonucleotides complementary to polynucleotides encoding one or more kallikrein polypeptides, which are overexpressed in renal cell carcinoma. In an alternative method, expression of genes corresponding to one or more kallikrein polypeptides which are underexpressed in renal cell carcinoma are increased.

35 The invention relates to a method of inhibiting renal cell carcinoma in a patient at risk for developing renal cell carcinoma comprising inhibiting or increasing expression (or overexpression) of genes encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, that are either overexpressed or underexpressed, in renal cell carcinoma.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become 5 apparent to those skilled in the art from this detailed description.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to newly discovered correlations between expression of certain markers and renal cell carcinoma. The combinations of markers described herein may provide sensitive methods for detecting renal cell carcinoma. The levels of expression of a combination of markers described herein may 10 correlate with the presence of renal cell carcinoma or a pre-malignant condition in a patient. Methods are provided for detecting the presence of renal cell carcinoma in a sample, the absence of renal cell carcinoma in a sample, the stage of a renal cell carcinoma, the grade of a renal cell carcinoma, the benign or malignant nature of a renal cell carcinoma, the metastatic potential of a renal cell carcinoma, assessing the histological type of neoplasm associated with the renal cell carcinoma, the indolence or aggressiveness of the cancer, and 15 other characteristics of renal cell carcinoma that are relevant to prevention, diagnosis, characterization, and therapy of renal cell carcinoma in a patient. Methods are also provided for assessing the efficacy of one or more test agents for inhibiting renal cell carcinoma, assessing the efficacy of a therapy for renal cell carcinoma, monitoring the progression of renal cell carcinoma, selecting an agent or therapy for inhibiting renal cell carcinoma, treating a patient afflicted with renal cell carcinoma, inhibiting renal cell carcinoma in a 20 patient, and assessing the carcinogenic potential of a test compound.

Glossary

The terms "sample", "biological sample", and the like, mean a material known or suspected of expressing or containing kallikrein polypeptides associated with renal cell carcinoma, or polynucleotides encoding the polypeptides. The test sample can be used directly as obtained from the source or following a 25 pretreatment to modify the character of the sample. The sample can be derived from any biological source, such as tissues, extracts, or cell cultures, including cells (e.g. tumor cells), cell lysates, and physiological fluids, such as, for example, whole blood, plasma, serum, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, synovial fluid, peritoneal fluid and the like. The sample can be obtained from animals, preferably mammals, most preferably humans. The sample can be treated prior to use, such as 30 preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of interfering components, the addition of reagents, and the like. Nucleic acids and polypeptides may be isolated from the samples and utilized in the methods of the invention. In a preferred embodiment, the sample is a serum sample.

The term "subject" or "patient" refers to a warm-blooded animal such as a mammal, which is 35 suspected of having renal cell carcinoma or a condition, disease, or syndrome associated with renal cell carcinoma. Preferably, "subject" refers to a human.

"Kallikrein polypeptides" or "kallikrein markers" include one or more of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The term includes the native-sequence polypeptides, isoforms, precursors and chimeric polypeptides. The amino acid sequences for native kallikrein polypeptides employed in the

present invention include the sequences found in GenBank for each polypeptide as shown in Table 1, and in SEQ ID NO: 1 (kallikrein 5), NO. 4 (kallikrein 6), NO. 8 (kallikrein 10), and NOs. 11 and 12 (kallikrein 11), or a portion thereof. Other useful polypeptides are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity), and preferably retain the immunogenic activity of the corresponding native-sequence kallikrein polypeptide.

A "native-sequence polypeptide" comprises a polypeptide having the same amino acid sequence of a polypeptide derived from nature. Such native-sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.

10 The term "native-sequence polypeptide" specifically encompasses naturally occurring truncated or secreted forms of a polypeptide, polypeptide variants including naturally occurring variant forms (e.g., alternatively spliced forms or splice variants), and naturally occurring allelic variants.

15 The term "polypeptide variant" means a polypeptide having at least about 70-80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with a native-sequence polypeptide, in particular having at least 70-80%, 85%, 90%, 95% amino acid sequence identity to the sequences identified in the GenBank Accession Nos. in Table 1 and shown in SEQ ID NOS 1, 4, 8, 11, and 12. Such variants include, for instance, polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of SEQ ID NOS: 1, 4, 8, 11, and 12, including variants from other species, but excludes a native-sequence polypeptide.

20 An allelic variant may also be created by introducing substitutions, additions, or deletions into a nucleic acid encoding a native polypeptide sequence such that one or more amino acid substitutions, additions, or deletions are introduced into the encoded protein. Mutations may be introduced by standard methods, such as site-directed mutagenesis and PCR-mediated mutagenesis. In an embodiment, conservative substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue with a similar side chain. Amino acids with similar side chains are known in the art and include amino acids with basic side chains (e.g. Lys, Arg, His), acidic side chains (e.g. Asp, Glu), uncharged polar side chains (e.g. Gly, Asp, Glu, Ser, Thr, Tyr and Cys), nonpolar side chains (e.g. Ala, Val, Leu, Iso, Pro, Trp), beta-branched side chains (e.g. Thr, Val, Iso), and aromatic side chains (e.g. Tyr, Phe, Trp, His). Mutations can also be introduced randomly along part or all of the native sequence, for example, by saturation mutagenesis. Following mutagenesis the variant polypeptide can be recombinantly expressed and the activity of the polypeptide may be determined.

25 Polypeptide variants include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of a native polypeptide which include fewer amino acids than the full length polypeptides. A portion of a polypeptide can be a polypeptide which is for example, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids in length. Portions in which regions of a polypeptide are deleted can be prepared by recombinant techniques and can be evaluated for one or more functional activities such as the ability to form antibodies specific for a polypeptide.

A naturally occurring allelic variant may contain conservative amino acid substitutions from the native polypeptide sequence or it may contain a substitution of an amino acid from a corresponding position in a kallikrein polypeptide homolog, for example, the murine kallikrein polypeptide.

Percent identity of two amino acid sequences, or of two nucleic acid sequences identified herein is 5 defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical with the amino acid residues in a kallikrein polypeptide or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid or nucleic acid sequence identity can be achieved in various conventional 10 ways, for instance, using publicly available computer software including the GCG program package (Devereux J. et al., Nucleic Acids Research 12(1): 387, 1984); BLASTP, BLASTN, and FASTA (Altschul, S.F. et al. J. Molec. Biol. 215: 403-410, 1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCBI NLM NIH Bethesda, Md. 20894; Altschul, S. et al. J. Mol. Biol. 215: 403-410, 1990). Skilled artisans can determine appropriate parameters for measuring 15 alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Methods to determine identity and similarity are codified in publicly available computer programs.

Kallikrein polypeptides include chimeric or fusion proteins. A "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of a kallikrein polypeptide operably linked to a 20 heterologous polypeptide (i.e., a polypeptide other than the same kallikrein polypeptide). Within the fusion protein, the term "operably linked" is intended to indicate that the kallikrein polypeptide and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of the kallikrein polypeptide. A useful fusion protein is a GST fusion protein in which a kallikrein polypeptide is fused to the C-terminus of GST sequences. Another example of a fusion 25 protein is an immunoglobulin fusion protein in which all or part of a kallikrein polypeptide is fused to sequences derived from a member of the immunoglobulin protein family. Chimeric and fusion proteins can be produced by standard recombinant DNA techniques.

Kallikrein polypeptides may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these 30 and similar techniques.

"Kallikrein polynucleotides" or "polynucleotides encoding kallikrein polypeptides" refers to one or more of kallikrein 5 polynucleotide (KLK5), kallikrein 6 polynucleotide (KLK6), kallikrein 10 polynucleotide (KLK10), and kallikrein 11 polynucleotide (KLK11). The term includes polynucleotides that encode a native-sequence polypeptide, a polypeptide variant including a portion of a kallikrein polypeptide, 35 an isoform, precursor, and chimeric polypeptide.

The polynucleotide sequences encoding native kallikrein polypeptides employed in the present invention include the nucleic acid sequences of the GenBank Accession Nos. identified in Table 1, and in SEQ ID NOs: 2 and 3 (KLK5), NOs. 5, 6, and 7 (KLK6), NOs. 9 and 10 (KLK10), and NOs. 13 and 14 (KLK11), or a fragment thereof.

- 10 -

Polynucleotides encoding kallikrein polypeptides include nucleic acid sequences complementary to these nucleic acids, and polynucleotides that are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity).

5 Kallikrein polynucleotides also include sequences which differ from a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 3, 5, 6, 7, 9, 10, 13, and 14, due to degeneracy in the genetic code. As one example, DNA sequence polymorphisms within the nucleotide sequence of a kallikrein polypeptide may result in silent mutations that do not affect the amino acid sequence. Variations in one or more nucleotides may exist among individuals within a population due to
10 natural allelic variation. DNA sequence polymorphisms may also occur which lead to changes in the amino acid sequence of a kallikrein polypeptide.

Kallikrein polynucleotides also include nucleic acids that hybridize under stringent conditions, preferably high stringency conditions to a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 3, 5, 6, 7, 9, 10, 13, and 14. Appropriate stringency conditions which
15 promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C may be employed. The stringency may be selected based on the conditions used in the wash step. By way of example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In
20 addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

Kallikrein polynucleotides also include truncated nucleic acids or nucleic acid fragments and variant forms of the nucleic acids that arise by alternative splicing of an mRNA corresponding to a DNA.

Kallikrein polynucleotides are intended to include DNA and RNA (e.g. mRNA) and can be either double stranded or single stranded. A polynucleotide may, but need not, include additional coding or non-
25 coding sequences, or it may, but need not, be linked to other molecules and/or carrier or support materials. The polynucleotides for use in the methods of the invention may be of any length suitable for a particular method.

One or more kallikrein polypeptides or kallikrein polynucleotides are detected in the present invention. In an aspect, the kallikrein polypeptides comprise kallikrein 6; kallikrein 6 and kallikrein 10;
30 kallikrein 6 and kallikrein 11; kallikrein 6, kallikrein 10 and kallikrein 11; or kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11. In another aspect, the kallikrein polynucleotides comprise KLK6; KLK6 and KLK10; KLK6 and KLK11; KLK6, KLK10 and KLK11; or KLK5, KLK6, KLK10 and KLK11

General Methods

A variety of methods can be employed for the diagnostic and prognostic evaluation of renal cell
35 carcinoma involving kallikrein polypeptides, and polynucleotides encoding the polypeptides, and the identification of subjects with a predisposition to such disorders. Such methods may, for example, utilize polynucleotides encoding kallikrein polypeptides, and fragments thereof, and binding agents (e.g. antibodies aptamers) against kallikrein polypeptides, including peptide fragments. In particular, the polynucleotides and antibodies may be used, for example, for (1) the detection of either over- or under-expression of kallikrein

polynucleotides, relative to a non-disorder state; and (2) the detection of either an over- or an under-abundance of kallikrein polypeptides, relative to a non-disorder state or the presence of modified (e.g., less than full length) kallikrein polypeptides that correlate with a disorder state, or a progression toward a disorder state.

5 The invention also contemplates a method for detecting renal cell carcinoma comprising producing a profile of levels of kallikrein polypeptides in cells from a patient, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 10, and/or kallikrein 11, and comparing the profile with a reference to identify a protein profile for the test cells indicative of disease.

10 The methods described herein may be used to evaluate the probability of the presence of malignant or pre-malignant cells, for example, in a group of cells freshly removed from a host. Such methods can be used to detect tumors, quantitate their growth, and help in the diagnosis and prognosis of disease. The methods can be used to detect the presence of cancer metastasis, as well as confirm the absence or removal of all tumor tissue following surgery, cancer chemotherapy, and/or radiation therapy. They can further be used to monitor cancer chemotherapy and tumor reappearance.

15 The methods described herein can be adapted for diagnosing and monitoring renal cell carcinoma by detecting kallikrein polypeptides, or polynucleotides encoding the polypeptides in biological samples from a subject. These applications require that the amount of polypeptides or polynucleotides quantitated in a sample from a subject being tested be compared to a predetermined standard. The standard may correspond to levels quantitated for another sample or an earlier sample from the subject, or levels quantitated for a 20 control sample. Levels for control samples from healthy subjects or renal cell carcinoma subjects may be established by prospective and/or retrospective statistical studies. Healthy or normal subjects who have no clinically evident disease or abnormalities may be selected for statistical studies. Diagnosis may be made by a finding of statistically different levels of kallikrein polypeptides, or polynucleotides encoding same, compared to a control sample or previous levels quantitated for the same subject. A "significant difference" 25 in levels of markers or polynucleotides in a patient sample compared to a control or standard (e.g. normal levels or levels in other samples from a patient) may represent levels that are higher or lower than the standard error of the detection assay, preferably the levels are at least about 1.5, 2, 3, 4, 5, or 6 times higher or lower, respectively, than the control or standard. The difference in levels of markers or polynucleotides may be a statistically significant difference.

30 In an embodiment, the levels of kallikrein markers, in particular kallikrein 6 and kallikrein 10, are significantly higher in subjects with renal cell carcinoma, more particularly renal cell carcinoma with tumors of high grade and/or advanced stage. In another embodiment, there is a statistically significant difference in kallikrein 6 levels and/or kallikrein 10 levels which are indicative of late stage disease and/or reduced disease survival.

35 **Nucleic Acid Methods/Assays**

As noted herein renal cell carcinoma may be detected based on the level of polynucleotides encoding kallikrein polypeptides in a sample. Techniques for detecting nucleic acid molecules such as polymerase chain reaction (PCR) and hybridization assays are well known in the art.

Nucleotide probes for use in the detection of nucleic acid sequences in samples may be constructed using conventional methods known in the art. Suitable probes may be based on nucleic acid sequences encoding at least 5 sequential amino acids from regions of polynucleotides encoding kallikrein polypeptides, preferably they comprise 15 to 40 nucleotides. A nucleotide probe may be labeled with a detectable substance such as a radioactive label that provides for an adequate signal and has sufficient half-life such as ^{32}P , ^{3}H , ^{14}C or the like. Other detectable substances that may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labeled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect polynucleotides encoding kallikrein polypeptides preferably in human cells. The nucleotide probes may also be useful in the diagnosis of renal cell carcinoma involving polynucleotides encoding kallikrein polypeptides, in monitoring the progression of such disorder; or monitoring a therapeutic treatment.

Probes may be used in hybridization techniques to detect polynucleotides encoding kallikrein polypeptides. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from a patient or other cellular source with probes under conditions favorable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of nucleic acids that have hybridized to the probe if any are detected.

The detection of polynucleotides encoding kallikrein polypeptides, may involve the amplification of specific gene sequences using an amplification method such as polymerase chain reaction (PCR), followed by the analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed by one of skill in the art.

By way of example, oligonucleotide primers may be employed in a PCR based assay to amplify a portion of polynucleotides encoding kallikrein polypeptides, derived from a sample, wherein the oligonucleotide primers are specific for (i.e. hybridize to) polynucleotides encoding each of the kallikrein polypeptides. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis.

In order to maximize hybridization under assay conditions, primers and probes employed in the methods of the invention generally have at least about 60%, preferably at least about 75% and more preferably at least about 90% identity to a portion of polynucleotides encoding kallikrein polypeptides. The primers and probes may be at least 10 nucleotides, and preferably at least 20 nucleotides in length. In an embodiment the primers and probes are at least about 10-40 nucleotides in length.

Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of expression of polynucleotides encoding kallikrein polypeptides. For example, RNA may be isolated from a cell type or tissue known to express these polynucleotides and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein.

The primers and probes may be used in the above-described methods *in situ* i.e directly on tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections.

In an aspect of the invention, a method is provided employing reverse transcriptase-polymerase chain reaction (RT-PCR), in which PCR is applied in combination with reverse transcription. Generally, 5 RNA is extracted from a sample tissue using standard techniques (for example, guanidine isothiocyanate extraction as described by Chomcynski and Sacchi, *Anal. Biochem.* 162:156-159, 1987) and is reverse transcribed to produce cDNA. The cDNA is used as a template for a polymerase chain reaction. The cDNA is hybridized to sets of primers specifically designed against a kallikrein polynucleotide sequence. Once the primer and template have annealed a DNA polymerase is employed to extend from the primer, to synthesize 10 a copy of the template. The DNA strands are denatured, and the procedure is repeated many times until sufficient DNA is generated to allow visualization by ethidium bromide staining and agarose gel electrophoresis.

Amplification may be performed on samples obtained from a subject with suspected renal cell carcinoma and an individual who is not afflicted with renal cell carcinoma. The reaction may be performed 15 on several dilutions of cDNA spanning at least two orders of magnitude. A statistically significant difference in expression in several dilutions of the subject sample as compared to the same dilutions of the non-cancerous sample may be considered positive for the presence of renal cell carcinoma.

Oligonucleotides or longer fragments derived from polynucleotides encoding each kallikrein polypeptide may be used as targets in a microarray. The microarray can be used to simultaneously monitor 20 the expression levels of large numbers of genes. The information from the microarray may be used to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

The preparation, use, and analysis of microarrays are well known to a person skilled in the art. (See, for example, Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, et al. (1996) *Proc. Natl. Acad. Sci.* 93:10614-10619; Baldeschweiler et al. (1995), PCT Application WO95/251116; Shalon, D. et al. (I 995) 25 PCT application WO95/35505; Heller, R. A. et al. (1997) *Proc. Natl. Acad. Sci.* 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)

Thus the invention also includes an array comprising polynucleotides encoding kallikrein marker(s). The array can be used to assay expression of kallikrein polynucleotides in the array. The invention allows the quantitation of expression of polynucleotides encoding kallikrein markers.

30 In an embodiment, the array can be used to monitor the time course of expression of kallikrein polynucleotides in the array. This can occur in various biological contexts such as tumor progression.

The array is also useful for ascertaining differential expression patterns of kallikrein polynucleotides in normal and abnormal cells. This provides a battery of polynucleotides that could serve as molecular targets for diagnosis or therapeutic intervention.

35 **Protein Methods**

Binding agents specific for kallikrein polypeptides may be used for a variety of diagnostic and assay applications. There are a variety of assay formats known to the skilled artisan for using a binding agent to detect a target molecule in a sample. (For example, see Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988). In general, the presence or absence of an renal cell

carcinoma in a subject may be determined by (a) contacting a sample from the subject with binding agents for kallikrein polypeptides; (b) detecting in the sample levels of polypeptides that bind to the binding agents; and (c) comparing the levels of polypeptides with a predetermined standard or cut-off value.

“Binding agent” refers to a substance such as a polypeptide or antibody that specifically binds to a kallikrein polypeptide. A substance “specifically binds” to a polypeptide if it reacts at a detectable level with the kallikrein polypeptide, and does not react detectably with peptides containing unrelated sequences or sequences of different polypeptides. Binding properties may be assessed using an ELISA, which may be readily performed by those skilled in the art (see for example, Newton et al, *Develop. Dynamics* 197: 1-13, 1993).

10 A binding agent may be a ribosome, with or without a peptide component, an aptamer, an RNA molecule, or a polypeptide. A binding agent may be a polypeptide that comprises a kallikrein polypeptide sequence, a peptide variant thereof, or a non-peptide mimetic of such a sequence. By way of example a kallikrein polypeptide sequence may be a peptide portion of a kallikrein polypeptide that is capable of modulating a function mediated by the kallikrein polypeptide.

15 An aptamer includes a DNA or RNA molecule that binds to polynucleotides and polypeptides. An aptamer that binds to a polypeptide (or binding domain) of a kallikrein polypeptide or a polynucleotide encoding a kallikrein polypeptide can be produced using conventional techniques, without undue experimentation. [For example, see the following publications describing *in vitro* selection of aptamers: Klug et al., *Mol. Biol. Reports* 20:97-107 (1994); Wallis et al., *Chem. Biol.* 2:543-552 (1995); Ellington, *Curr. Biol.* 4:427-429 (1994); Lato et al., *Chem. Biol.* 2:291-303 (1995); Conrad et al., *Mol. Div.* 1:69-78 (1995); and Uphoff et al., *Curr. Opin. Struct. Biol.* 6:281-287 (1996)].

In certain other preferred embodiments, the binding agent is an antibody.

20 In an aspect the present invention provides a diagnostic method for monitoring or diagnosing renal cell carcinoma in a subject by quantitating kallikrein polypeptides, in a biological sample from the subject comprising reacting the sample with antibodies specific for kallikrein polypeptides, which are directly or indirectly labelled with detectable substances, and detecting the detectable substances.

In an aspect of the invention, a method for detecting renal cell carcinoma is provided comprising:

- (a) obtaining a sample suspected of containing kallikrein polypeptides associated with renal cell carcinoma, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11;
- (b) contacting the sample with antibodies that specifically bind kallikrein polypeptides, under conditions effective to bind the antibodies and form complexes;
- (c) measuring the amount of kallikrein polypeptides, present in the sample by quantitating the amount of the complexes; and
- (d) comparing the amount of kallikrein polypeptides, present in the samples with the amount of polypeptides in a control, wherein a change or significant difference in the amount of polypeptides in the sample compared with the amount in the control is indicative of renal cell carcinoma.

In an embodiment, the invention contemplates a method for monitoring the progression of renal cell carcinoma in an individual, comprising:

- (a) contacting antibodies which bind to kallikrein polypeptides, with a sample from the individual so as to form binary complexes comprising each of the antibodies and polypeptides in the sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11;
- (b) determining or detecting the presence or amount of complex formation in the sample;
- (c) repeating steps (a) and (b) at a point later in time; and
- (d) comparing the result of step (b) with the result of step (c), wherein a difference in the amount of complex formation is indicative of the stage and/or progression of the renal cell carcinoma in said individual.

The amount of complexes may also be compared to a value representative of the amount of the complexes from an individual not at risk of, or afflicted with, renal cell carcinoma at different stages.

Thus, antibodies specifically reactive with a kallikrein polypeptide, or derivatives, such as enzyme conjugates or labeled derivatives, may be used to detect a kallikrein polypeptide, in various samples (e.g. biological materials). They may be used as diagnostic or prognostic reagents and they may be used to detect abnormalities in the levels of expression of kallikrein polypeptides, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular location of kallikrein polypeptides. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on renal cell carcinoma involving kallikrein polypeptides, and other conditions. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies.

Antibodies may be used in any known immunoassays that rely on the binding interaction between antigenic determinants of kallikrein polypeptides, and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, and histochemical tests. These terms are well understood by those skilled in the art. A person skilled in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

In particular, the antibodies may be used in immunohistochemical analyses, for example, at the cellular and sub-subcellular level, to detect kallikrein polypeptides, to localize them to particular renal cell carcinoma tumor cells and tissues, and to specific subcellular locations, and to quantitate the level of expression.

Antibodies for use in the present invention include monoclonal or polyclonal antibodies, immunologically active fragments (e.g. a Fab or (Fab)₂ fragments), antibody heavy chains, humanized antibodies, antibody light chains, genetically engineered single chain F_v molecules (Ladner et al, U.S. Pat. No. 4,946,778), chimeric antibodies, for example, antibodies which contain the binding specificity of murine antibodies, but in which the remaining portions are of human origin, or derivatives, such as enzyme conjugates or labeled derivatives.

Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art. Isolated native or recombinant kallikrein

- 16 -

polypeptides may be utilized to prepare antibodies. See, for example, Kohler et al. (1975) *Nature* 256:495-497; Kozbor et al. (1985) *J. Immunol Methods* 81:31-42; Cote et al. (1983) *Proc Natl Acad Sci* 80:2026-2030; and Cole et al. (1984) *Mol Cell Biol* 62:109-120 for the preparation of monoclonal antibodies; Huse et al. (1989) *Science* 246:1275-1281 for the preparation of monoclonal Fab fragments; and, Pound (1998) 5 *Immunochemical Protocols*, Humana Press, Totowa, N.J for the preparation of phagemid or B-lymphocyte immunoglobulin libraries to identify antibodies. The antibodies specific for kallikrein polypeptides used in the methods of the invention may also be obtained from scientific or commercial sources.

In an embodiment of the invention, antibodies are reactive against kallikrein polypeptides if they bind with a K_a of greater than or equal to 10^7 M.

10 Antibodies that bind to kallikrein polypeptides may be labelled with a detectable substance and localised in biological samples based upon the presence of the detectable substance. Examples of detectable substances include, but are not limited to, the following: radioisotopes (e.g., 3 H, 14 C, 35 S, 125 I, 131 I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent labels such as luminol, enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, 15 acetylcholinesterase), biotinyl groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods), and predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be 20 coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

25 Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against a kallikrein polypeptide. The second antibody may be labeled with a detectable substance to detect the primary antigen-antibody reaction. By way of example, if the antibody having specificity against a kallikrein polypeptide is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

30 Methods for conjugating or labelling the antibodies discussed above may be readily accomplished by one of ordinary skill in the art. (See for example Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wilchek (eds.), Academic Press, New York, p. 30, 1974; and Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988 re methods for conjugating or labelling the antibodies with enzyme or ligand binding partner).

35 Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect kallikrein polypeptides. Generally, antibodies may be labeled with detectable substances and kallikrein polypeptides, may be localised in tissues and cells based upon the presence of the detectable substance.

In the context of the methods of the invention, the sample, binding agents (e.g. antibodies) for kallikrein polypeptides may be immobilized on a carrier or support. Examples of suitable carriers or

supports are agarose, cellulose, nitrocellulose, dextran, Sephadex, Sepharose, liposomes, carboxymethyl cellulose, polyacrylamides, polystyrene, gabbros, filter paper, magnetite, ion-exchange resin, plastic film, plastic tube, glass, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The support material may have any possible configuration including 5 spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test strip). Thus, the carrier may be in the shape of, for example, a tube, test plate, well, beads, disc, sphere, etc. The immobilized material may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical methods, for example, cyanogen bromide coupling. Binding agents (e.g. antibodies) may be indirectly immobilized using second binding agents specific for the 10 first binding agent. For example, mouse antibodies specific for a kallikrein polypeptide may be immobilized using sheep anti-mouse IgG Fc fragment specific antibody coated on the carrier or support.

Where radioactive labels are used as a detectable substance, kallikrein polypeptides may be localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

15 Time-resolved fluorometry may be used to detect a signal. For example, the method described in Christopoulos TK and Diamandis EP Anal Chem 1992:64:342-346 may be used with a conventional time-resolved fluorometer.

Therefore, in accordance with an embodiment of the invention, a method is provided wherein 20 antibodies specific for each kallikrein polypeptide, are labelled with enzymes, substrates for the enzymes are added wherein the substrates are selected so that the substrates, or a reaction product of the enzymes and substrates, form fluorescent complexes with lanthanide metals. Lanthanide metals are added and the kallikrein polypeptides are quantitated in the sample by measuring fluorescence of the fluorescent 25 complexes. Antibodies specific for the kallikrein polypeptides may be directly or indirectly labelled with enzymes. Enzymes are selected based on the ability of a substrate of the enzyme, or a reaction product of the enzyme and substrate, to complex with lanthanide metals such as europium and terbium. Examples of suitable enzymes include alkaline phosphatase and β -galactosidase.

30 Examples of enzymes and substrates for enzymes that provide such fluorescent complexes are described in U.S. Patent No. 5,312,922 to Diamandis. By way of example, when the antibody is directly or indirectly labelled with alkaline phosphatase the substrate employed in the method may be 4-methylumbelliferyl phosphate, 5-fluorosalicyl phosphate, or diflunisal phosphate. The fluorescence intensity 35 of the complexes is typically measured using a time-resolved fluorometer e.g. a CyberFluor 615 Imunoanalyzer (Nordion International, Kanata, Ontario).

Antibodies specific for kallikrein polypeptides may also be indirectly labelled with enzymes. For example, an antibody may be conjugated to one partner of a ligand binding pair, and the enzyme may be 35 coupled to the other partner of the ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein. In another embodiment, antibodies specific for the anti-kallikrein antibodies are labeled with an enzyme.

In accordance with an embodiment, the present invention provides means for determining kallikrein polypeptides in a sample, in particular a serum sample, by measuring kallikrein polypeptides by

immunoassay. It will be evident to a skilled artisan that a variety of immunoassay methods can be used to measure kallikrein polypeptides in serum. In general, an immunoassay method may be competitive or noncompetitive. Competitive methods typically employ immobilized or immobilizable antibodies to the kallikrein polypeptides and a labeled form of each of the kallikrein polypeptides. Kallikrein polypeptides and 5 labeled kallikrein polypeptides compete for binding to anti-kallikrein antibodies. After separation of the resulting labeled kallikrein polypeptides that have become bound to anti-kallikrein polypeptides (bound fraction) from that which has remained unbound (unbound fraction), the amount of the label in either bound or unbound fraction is measured and may be correlated with the amount of kallikrein polypeptides, in the test sample in any conventional manner, e.g., by comparison to a standard curve.

10 In an aspect, a non-competitive method is used for the determination of kallikrein polypeptides with the most common method being the "sandwich" method. In this assay, two types of antibodies specific for kallikrein polypeptides are employed. One type of antibody is directly or indirectly labeled (sometimes referred to as the "detection antibody") and the other is immobilized or immobilizable (sometimes referred to as the "capture antibody"). The capture and detection antibodies can be contacted simultaneously or 15 sequentially with a test sample. Sequential methods can be accomplished by incubating capture antibodies with the sample, and adding the detection antibodies at a predetermined time thereafter (sometimes referred to as the "forward" method); or the detection antibodies can be incubated with the sample first and then the capture antibodies added (sometimes referred to as the "reverse" method). After the necessary incubation(s) have occurred, to complete the assay, the capture antibodies are separated from the liquid test mixture, and 20 labels are measured in at least a portion of the separated capture antibody phase or the remainder of the liquid test mixture. Generally the labels are measured in the capture antibody phase since it comprises kallikrein polypeptides bound by ("sandwiched" between) the capture and detection antibodies. In an embodiment, the label may be measured without separating the capture antibodies and liquid test mixture.

25 In a typical two-site immunometric assay for kallikrein polypeptides, one or both of the capture and detection antibodies are polyclonal antibodies or one or both of the capture and detection antibodies are monoclonal antibodies (i.e. polyclonal/polyclonal, monoclonal/monoclonal, or monoclonal/polyclonal). The labels used with the detection antibodies can be selected from any of those known conventionally in the art. The labels may be an enzyme or a chemiluminescent moiety, but it can also be a radioactive isotope, a 30 fluorophor, a detectable ligand (e.g., detectable by a secondary binding by a labeled binding partner for the ligand), and the like. Preferably antibodies are labelled with enzymes which are detected by adding substrates that are selected so that a reaction product of the enzymes and substrates forms fluorescent complexes. Capture antibodies may be selected so that they provide a means for being separated from the remainder of the test mixture. Accordingly, the capture antibodies can be introduced to the assay in an already immobilized or insoluble form, or can be in an immobilizable form, that is, a form which enables 35 immobilization to be accomplished subsequent to introduction of the capture antibodies to the assay. An immobilized capture antibody may comprise an antibody covalently or noncovalently attached to a solid phase such as a magnetic particle, a latex particle, a microtiter plate well, a bead, a cuvette, or other reaction vessel. An example of an immobilizable capture antibody is antibody which has been chemically modified with a ligand moiety, e.g., a hapten, biotin, or the like, and which can be subsequently immobilized by

contact with an immobilized form of a binding partner for the ligand, e.g., an antibody, avidin, or the like. In an embodiment, a capture antibody may be immobilized using a species specific antibody for the capture antibody that is bound to the solid phase.

A particular sandwich immunoassay method of the invention employs two types of antibodies, first 5 antibodies are reactive against kallikrein polypeptides and second antibodies having specificity against antibodies reactive against kallikrein polypeptides labelled with enzymatic labels, and fluorogenic substrates for the enzymes. An enzyme may be alkaline phosphatase (ALP) and the substrate is 5-fluorosalicyl phosphate. ALP cleaves phosphate out of the fluorogenic substrate, 5-fluorosalicyl phosphate, to produce 5-fluorosalicylic acid (FSA). 5-Fluorosalicylic acid can then form a highly fluorescent ternary complex of the 10 form FSA-Tb(3+)-EDTA, which can be quantified by measuring the Tb3+ fluorescence in a time-resolved mode. Fluorescence intensity is measured using a time-resolved fluorometer as described herein.

The above-described immunoassay methods and formats are intended to be exemplary and are not limiting.

Computer Systems

15 Computer readable media comprising kallikrein markers is also provided. "Computer readable media" refers to any medium that can be read and accessed directly by a computer, including but not limited to magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. Thus, the invention contemplates computer readable 20 medium having recorded thereon markers identified for patients and controls.

"Recorded" refers to a process for storing information on computer readable medium. The skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising information on kallikrein markers.

25 A variety of data processor programs and formats can be used to store information on kallikrein markers on computer readable medium. For example, the information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. Any number of dataprocessor structuring formats (e.g., text file or database) may be adapted in order to obtain computer readable medium having recorded thereon the marker information.

30 By providing the marker information in computer readable form, one can routinely access the information for a variety of purposes. For example, one skilled in the art can use the information in computer readable form to compare marker information obtained during or following therapy with the information stored within the data storage means.

35 The invention provides a medium for holding instructions for performing a method for determining whether a patient has renal cell carcinoma or a pre-disposition to renal cell carcinoma, comprising determining the presence or absence of kallikrein markers or polynucleotides encoding same, and based on the presence or absence of the kallikrein markers or polynucleotides encoding same, determining whether the patient has renal cell carcinoma or a pre-disposition to renal cell carcinoma, and optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention also provides in an electronic system and/or in a network, a method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same, comprising determining the presence or absence of kallikrein markers or polynucleotides encoding same, and based on the presence or absence of the kallikrein markers or polynucleotides encoding same, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma, and optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention further provides in a network, a method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same, comprising: (a) receiving phenotypic information on the subject and information on kallikrein markers or polynucleotides encoding same, associated with samples from the subject; (b) acquiring information from the network corresponding to the kallikrein markers or polynucleotides encoding same; and (c) based on the phenotypic information and information on the kallikrein markers or polynucleotides encoding same, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma; and (d) optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention still further provides a system for identifying selected records that identify a renal cell carcinoma cell. A system of the invention generally comprises a digital computer; a database server coupled to the computer; a database coupled to the database server having data stored therein, the data comprising records of data comprising kallikrein markers, or polynucleotides encoding same, and a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records which match the desired selection criteria.

In an aspect of the invention a method is provided for detecting a renal cell carcinoma cell using a computer having a processor, memory, display, and input/output devices, the method comprising the steps of:

- (a) creating records of kallikrein markers or polynucleotides encoding same, isolated from a sample suspected of containing an renal cell carcinoma cell;
- (b) providing a database comprising records of data comprising kallikrein markers, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and/or comprising polynucleotides encoding same; and
- (c) using a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records of step (a) which provide a match of the desired selection criteria of the database of step (b) the presence of a match being a positive indication that the markers of step (a) have been isolated from a cell that is a renal cell carcinoma cell.

The invention contemplates a business method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same comprising: (a) receiving phenotypic information on the subject and information on kallikrein markers or polynucleotides encoding same, associated with samples from the subject; (b) acquiring

information from a network corresponding to the kallikrein markers or polynucleotides encoding same; and (c) based on the phenotypic information, information on the kallikrein markers or polynucleotides encoding same, and acquired information, determining whether the subject has renal cell carcinoma or a predisposition to renal cell carcinoma; and (d) optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

Imaging Methods

Antibodies specific for kallikrein polypeptides may also be used in imaging methodologies in the management of renal cell carcinoma. The invention provides a method for imaging tumors associated with kallikrein polypeptides.

10 In an embodiment the method is an *in vivo* method and a subject or patient is administered imaging agents that carry imaging labels and are capable of targeting or binding to kallikrein polypeptides. In the method each imaging agent is labeled so that it can be distinguished during the imaging. The imaging agents are allowed to incubate *in vivo* and bind to the kallikrein polypeptides associated with renal cell carcinoma tumors. The presence of label is localized to the renal cell carcinoma, and the localized label is detected 15 using imaging devices known to those skilled in the art.

20 The imaging agents may be antibodies or chemical entities that recognize kallikrein polypeptides. In an aspect of the invention an imaging agent is a polyclonal antibody or monoclonal antibody, or fragments thereof, or constructs thereof including but not limited to, single chain antibodies, bifunctional antibodies, molecular recognition units, and peptides or entities that mimic peptides. The antibodies specific for kallikrein polypeptides used in the methods of the invention may be obtained from scientific or commercial sources, or isolated native or recombinant kallikrein polypeptides may be utilized to prepare antibodies etc as described herein.

25 An imaging agent may be a peptide that mimics the epitope for an antibody specific for a kallikrein polypeptide and binds to a kallikrein polypeptide. The peptide may be produced on a commercial synthesizer using conventional solid phase chemistry. By way of example, a peptide may be prepared that includes tyrosine, lysine, or phenylalanine to which N₂S₂ chelate is complexed (See U.S. Patent No. 4,897,255). The anti-kallikrein peptide conjugate is then combined with a radiolabel (e.g. sodium ^{99m}Tc pertechnetate or sodium ¹⁸⁸Re perrhenate) and it may be used to locate a tumor producing the kallikrein polypeptides.

30 Imaging agents carry labels to image the kallikrein polypeptides. Agents may be labelled for use in radionuclide imaging. In particular, agents may be directly or indirectly labelled with a radioisotope. Examples of radioisotopes that may be used in the present invention are the following: ²⁷⁷Ac, ²¹¹At, ¹²⁸Ba, ¹³¹Ba, ⁷Be, ²⁰⁴Bi, ²⁰⁵Bi, ²⁰⁶Bi, ⁷⁶Br, ⁷⁷Br, ⁸²Br, ¹⁰⁹Cd, ⁴⁷Ca, ¹¹C, ¹⁴C, ³⁶Cl, ⁴⁸Cr, ⁵¹Cr, ⁶²Cu, ⁶⁴Cu, ⁶⁷Cu, ¹⁶⁵Dy, ¹⁵⁵Eu, ¹⁸F, ¹⁵³Gd, ⁶⁶Ga, ⁶⁷Ga, ⁶⁸Ga, ⁷²Ga, ¹⁹⁸Au, ³H, ¹⁶⁶Ho, ¹¹¹In, ^{113m}In, ^{115m}In, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁹Ir, ^{191m}Ir, ¹⁹²Ir, ¹⁹⁴Ir, ⁵²Fe, ⁵⁵Fe, ⁵⁹Fe, ¹⁷⁷Lu, ¹⁵O, ^{191m-191}Os, ¹⁰⁹Pd, ³²P, ³³P, ⁴²K, ²²⁶Ra, ¹⁸⁶Re, ¹⁸⁸Re, ^{82m}Rb, ¹⁵³Sm, ⁴⁶Sc, ⁴⁷Sc, ⁷²Se, ⁷⁵Se, ¹⁰⁵Ag, ²²Na, ²⁴Na, ⁸⁹Sr, ³⁵S, ³⁸S, ¹⁷⁷Ta, ⁹⁶Tc, ^{99m}Tc, ²⁰¹Tl, ²⁰²Tl, ¹¹³Sn, ^{117m}Sn, ¹²¹Sn, ¹⁶⁶Yb, ¹⁶⁹Yb, ¹⁷⁵Yb, ⁸⁸Y, ⁹⁰Y, ⁶²Zn and ⁶⁵Zn. Preferably the radioisotope is ¹³¹I, ¹²⁵I, ¹²³I, ¹¹¹I, ^{99m}Tc, ⁹⁰Y, ¹⁸⁶Re, ¹⁸⁸Re, ³²P, ¹⁵³Sm, ⁶⁷Ga, ²⁰¹Tl, ⁷⁷Br, or ¹⁸F, and it is imaged with a photoscanning device.

Procedures for labeling biological agents with the radioactive isotopes are generally known in the art. U.S. Pat. No. 4,302,438 describes tritium labeling procedures. Procedures for iodinating, tritium labeling,

and ^{35}S labeling especially adapted for murine monoclonal antibodies are described by Goding, J. W. (supra, pp 124-126) and the references cited therein. Other procedures for iodinating biological agents, such as antibodies, binding portions thereof, probes, or ligands, are described in the scientific literature (see Hunter and Greenwood, *Nature* 144:945 (1962), David et al., *Biochemistry* 13:1014-1021 (1974), and U.S. Pat. Nos. 5 3,867,517 and 4,376,110). Iodinating procedures for agents are described by Greenwood, F. et al., *Biochem. J.* 89:114-123 (1963); Marchalonis, J., *Biochem. J.* 113:299-305 (1969); and Morrison, M. et al., *Immunochemistry*, 289-297 (1971). $^{99\text{m}}$ Tc-labeling procedures are described by Rhodes, B. et al. in Burchiel, S. et al. (eds.), *Tumor Imaging: The Radioimmunochemical Detection of Cancer*, New York: Masson 111-123 (1982) and the references cited therein. Labelling of antibodies or fragments with 10 technetium-99m are also described for example in U.S. Pat. No. 5,317,091, U.S. Pat. No. 4,478,815, U.S. Pat. No. 4,478,818, U.S. Pat. No. 4,472,371, U.S. Pat. No. Re 32,417, and U.S. Pat. No. 4,311,688. Procedures suitable for ^{111}In -labeling biological agents are described by Hnatowich, D. J. et al., *J. Immunol. Methods*, 65:147-157 (1983), Hnatowich, D. et al., *J. Applied Radiation*, 35:554-557 (1984), and Buckley, R. G. et al., *F.E.B.S.* 166:202-204 (1984).

15 An imaging agent may also be labeled with a paramagnetic isotope for purposes of an *in vivo* method of the invention. Examples of elements that are useful in magnetic resonance imaging include gadolinium, terbium, tin, iron, or isotopes thereof. (See, for example, Schaefer et al., (1989) *JACC* 14, 472-480; Shreve et al., (1986) *Magn. Reson. Med.* 3, 336-340; Wolf, G L., (1984) *Physiol. Chem. Phys. Med. NMR* 16, 93-95; Wesbey et al., (1984) *Physiol. Chem. Phys. Med. NMR* 16, 145-155; Runge et al., (1984) 20 *Invest. Radiol.* 19, 408-415 for discussions on *in vivo* nuclear magnetic resonance imaging.)

In the case of radiolabeled agents, the agents may be administered to the patient, localized to the tumor having one or more kallikrein polypeptides with which the agents bind, and detected or "imaged" *in vivo* using known techniques such as radionuclear scanning using, for example, a gamma camera or emission tomography. [See for example, A. R. Bradwell et al., "Developments in Antibody Imaging", 25 *Monoclonal Antibodies for Cancer Detection and Therapy*, R. W. Baldwin et al., (eds.), pp. 65-85 (Academic Press 1985)]. A positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can also be used where the radiolabel emits positrons (e.g., ^{11}C , ^{18}F , ^{15}O , and ^{13}N).

Whole body imaging techniques using radioisotope labeled agents can be used for locating both 30 primary tumors and tumors which have metastasized. Antibodies specific for kallikrein polypeptides or fragments thereof having the same epitope specificity, are bound to a suitable radioisotope, or a combination thereof, and administered parenterally. For renal cell carcinoma, administration preferably is intravenous. The bio-distribution of the labels can be monitored by scintigraphy, and accumulations of the labels can be related to the presence of renal cell carcinoma cells. Whole body imaging techniques are described in U.S. 35 Pat. Nos. 4,036,945 and 4,311,688. Other examples of agents useful for diagnosis and therapeutic use that can be coupled to antibodies and antibody fragments include metallothionein and fragments (see, U.S. Pat. No. 4,732,864). These agents are useful in diagnosis, staging and visualization of cancer, in particular renal cell carcinoma, so that surgical and/or radiation treatment protocols can be used more efficiently.

Screening Methods

The invention also contemplates methods for evaluating test agents or compounds for their ability to inhibit renal cell carcinoma or potentially contribute to renal cell carcinoma. Test agents and compounds include but are not limited to peptides such as soluble peptides including Ig-tailed fusion peptides, members 5 of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids, phosphopeptides (including members of random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)2, and Fab expression library fragments, and epitope-binding fragments thereof)], nucleic acids (e.g. antisense, interference RNA) and small organic or inorganic 10 molecules. The agents or compounds may be endogenous physiological compounds or natural or synthetic compounds.

The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, the method comprising comparing:

- (a) levels of kallikrein markers or polynucleotides encoding same in a first sample obtained 15 from a patient and exposed to the test agent, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and
- (b) levels of the kallikrein markers or polynucleotides encoding same in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of kallikrein markers or polynucleotides 20 encoding same in the first sample, relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting renal cell carcinoma in the patient.

The first and second samples may be portions of a single sample obtained from a patient or portions of pooled samples obtained from a patient.

In an aspect, the invention provides a method of selecting an agent for inhibiting renal cell 25 carcinoma in a patient comprising:

- (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing kallikrein markers and/or polynucleotides encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of 30 kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
- (d) selecting one of the test agents which alters the levels of the kallikrein markers and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.

Still another aspect of the present invention provides a method of conducting a drug discovery 35 business comprising:

- (a) providing one or more methods or assay systems for identifying agents that inhibit renal cell carcinoma in a patient;
- (b) conducting therapeutic profiling of agents identified in step (a), or further analogs thereof, for efficacy and toxicity in animals; and

(c) formulating a pharmaceutical preparation including one or more agents identified in step (b) as having an acceptable therapeutic profile.

In certain embodiments, the subject method can also include a step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and may optionally include establishing a 5 sales group for marketing the pharmaceutical preparation.

The invention also contemplates a method of assessing the renal cell carcinoma carcinogenic potential of a test compound comprising:

(a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and
10 (b) comparing kallikrein markers and/or polynucleotides encoding same in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the markers in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, 15 indicates that the test compound possesses renal cell carcinoma carcinogenic potential.

Kits

The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising at least kallikrein polynucleotides or binding agents (e.g. antibodies) described herein, which may be conveniently used, e.g., in clinical settings, to screen and diagnose patients, and to screen and 20 identify those individuals afflicted with or exhibiting a predisposition to renal cell carcinoma.

Thus, the invention also contemplates kits for carrying out the methods of the invention. Such kits typically comprise two or more components required for performing a diagnostic assay. Components include but are not limited to compounds, reagents, containers, and/or equipment.

In an embodiment, a container with a kit comprises binding agents as described herein. By way of 25 example, the kit may contain antibodies specific for kallikrein polypeptides, antibodies against the antibodies labelled with enzymes, and substrates for the enzymes. The kit may also contain microtiter plate wells, standards, assay diluent, wash buffer, adhesive plate covers, and/or instructions for carrying out a method of the invention using the kit.

In an aspect of the invention, the kit includes antibodies or antibody fragments which bind 30 specifically to epitopes of kallikrein polypeptides, and means for detecting binding of the antibodies to epitopes associated with tumor cells, either as concentrates (including lyophilized compositions), which may be further diluted prior to use or at the concentration of use, where the vials may include one or more dosages. Where the kits are intended for *in vivo* use, single dosages may be provided in sterilized containers, having the desired amount and concentration of agents. Containers that provide a formulation for direct use, 35 usually do not require other reagents, as for example, where the kit contains radiolabelled antibody preparations for *in vivo* imaging.

A kit may be designed to detect the level of polynucleotides encoding kallikrein polypeptides in a sample. Such kits generally comprise oligonucleotide probes or primers, as described herein, that hybridize to polynucleotides encoding kallikrein polypeptides. Such oligonucleotides may be used, for example, within

a PCR or hybridization procedure. Additional components that may be present within the kits include second oligonucleotides and/or diagnostic reagents to facilitate detection of polynucleotides encoding kallikrein polypeptides.

5 The reagents suitable for applying the screening methods of the invention to evaluate compounds may be packaged into convenient kits described herein providing the necessary materials packaged into suitable containers.

Applications

10 Kallikrein polypeptides are targets for renal cell carcinoma immunotherapy. Such immunotherapeutic methods include the use of antibody therapy, *in vivo* vaccines, and *ex vivo* immunotherapy approaches.

15 In one aspect, the invention provides antibodies specific for kallikrein polypeptides that may be used systemically to treat renal cell carcinoma. Preferably antibodies are used that target the tumor cells but not the surrounding non-tumor cells and tissue. Thus, the invention provides a method of treating a patient susceptible to, or having a cancer that expresses kallikrein polypeptides comprising administering to the patient an effective amount of antibodies that bind specifically to kallikrein polypeptides. In another aspect, the invention provides a method of inhibiting the growth of tumor cells expressing kallikrein polypeptides, comprising administering to a patient antibodies which bind specifically to kallikrein polypeptides in amounts effective to inhibit growth of the tumor cells. Antibodies specific for kallikrein polypeptides may also be used in a method for selectively inhibiting the growth of, or killing a cell expressing kallikrein 20 polypeptides comprising reacting antibody immunoconjugates or immunotoxins with the cell in an amount sufficient to inhibit the growth of, or kill the cell.

25 By way of example, unconjugated antibodies specific for kallikrein polypeptides may be introduced into a patient such that the antibodies bind to cancer cells expressing kallikrein polypeptides and mediate growth inhibition of such cells (including the destruction thereof), and the tumor, by mechanisms which may include complement-mediated cytolysis, antibody-dependent cellular cytotoxicity, altering the physiologic function of kallikrein polypeptides and/or the inhibition of ligand binding or signal transduction pathways. In addition to unconjugated antibodies, antibodies specific for kallikrein polypeptides, conjugated to therapeutic agents (e.g. immunoconjugates) may also be used therapeutically to deliver the agents directly to tumor cells expressing kallikrein polypeptides and thereby destroy the tumor. Examples of such agents include abrin, 30 ricin A, *Pseudomonas* exotoxin, or diphtheria toxin, proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, and biological response modifiers such as lymphokines, interleukin-1, interleukin-2, interleukin-6, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, or other growth factors.

35 Cancer immunotherapy using antibodies specific for kallikrein polypeptides may utilize the various approaches that have been successfully employed for cancers, including but not limited to colon cancer (Arlen et al., 1998, Crit Rev Immunol 18: 133-138), multiple myeloma (Ozaki et al., 1997, Blood 90: 3179-3186; Tsumenati et al., 1997, Blood 90: 2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res 52: 2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J Immunther Emphasis Tumor Immunol 19: 93-101), leukemia (Zhong et al., 1996, Leuk Res 20: 581-589), colorectal cancer (Moun et al., 1994, Cancer Res 54:

6160-6166); Velders et al., 1995, *Cancer Res* 55: 4398-4403), and breast cancer (Shepard et al., 1991, *J Clin Immunol* 11: 117-127).

In the practice of a method of the invention, antibodies specific for kallikrein polypeptides capable of inhibiting the growth of cancer cells expressing kallikrein polypeptides are administered in a 5 therapeutically effective amount to cancer patients whose tumors express or overexpress kallikrein polypeptides. The invention may provide a specific, effective and long-needed treatment for renal cell carcinoma. The antibody therapy methods of the invention may be combined with other therapies including chemotherapy and radiation.

Patients may be evaluated for the presence and levels of kallikrein polypeptides expression and 10 overexpression in tumors, preferably using immunohistochemical assessments of tumor tissue, quantitative imaging as described herein, or other techniques capable of reliably indicating the presence and degree of expression of kallikrein polypeptides. Immunohistochemical analysis of tumor biopsies or surgical specimens may be employed for this purpose.

Antibodies specific for kallikrein polypeptides useful in treating cancer include those that are 15 capable of initiating a potent immune response against the tumor and those that are capable of direct cytotoxicity. In this regard, the antibodies may elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites or complement proteins. In addition, antibodies specific for kallikrein polypeptides that exert a direct biological effect on tumor growth 20 are useful in the practice of the invention. Such antibodies may not require the complete immunoglobulin to exert the effect. Potential mechanisms by which such directly cytotoxic antibodies may act include inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism by which a particular antibody exerts an anti-tumor effect may be evaluated using any number of *in vitro* assays designed to determine ADCC, antibody-dependent 25 macrophage-mediated cytotoxicity (ADMMC), complement-mediated cell lysis, and others known in the art.

The anti-tumor activity of a combination of antibodies specific for kallikrein polypeptides may be evaluated *in vivo* using a suitable animal model. Xenogenic cancer models, wherein human cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice, may be employed.

30 The methods of the invention contemplate the administration of combinations, or "cocktails" of different individual antibodies recognizing epitopes of kallikrein polypeptides. Such cocktails may have certain advantages inasmuch as they contain antibodies that bind to different epitopes and/or exploit different effector mechanisms or combine directly cytotoxic antibodies with antibodies that rely on immune effector functionality. Such antibodies in combination may exhibit synergistic therapeutic effects. In addition, the 35 administration of the antibodies may be combined with other therapeutic agents, including but not limited to chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL2, GM-CSF). The antibodies may be administered in their "naked" or unconjugated form, or may have therapeutic agents conjugated to them.

The antibodies specific for kallikrein polypeptides used in the practice of the method of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material which when combined with the antibodies retains the anti-tumor function of the antibodies and is non-reactive with the subject's immune systems. Examples 5 include any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16.sup.th Edition, A. Osal., Ed., 1980).

Antibody formulations may be administered via any route capable of delivering the antibodies to the tumor site. Routes of administration include, but are not limited to, intravenous, intraperitoneal, 10 intramuscular, intratumor, intradermal, and the like. Preferably, the route of administration is by intravenous injection. Antibody preparations may be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.

Treatment will generally involve the repeated administration of the antibody preparation via an 15 acceptable route of administration such as intravenous injection (IV), at an effective dose. Dosages will depend upon various factors generally appreciated by those of skill in the art, including the type of cancer and the severity, grade, or stage of the cancer, the binding affinity and half life of the antibodies used, the degree of expression of kallikrein polypeptides in the patient, the extent of circulating kallikrein polypeptide 20 antigens the desired steady-state antibody concentration level, frequency of treatment, and the influence of any chemotherapeutic agents used in combination with a treatment method of the invention.

Daily doses may range from about 0.1 to 100 mg/kg. Doses in the range of 10-500 mg antibodies 25 per week may be effective and well tolerated, although even higher weekly doses may be appropriate and/or well tolerated. A determining factor in defining the appropriate dose is the amount of antibodies necessary to be therapeutically effective in a particular context. Repeated administrations may be required to achieve tumor inhibition or regression. Direct administration of antibodies specific for kallikrein polypeptides is also possible and may have advantages in certain situations.

Patients may be evaluated for kallikrein polypeptides, preferably in serum, in order to assist in the 30 determination of the most effective dosing regimen and related factors. The assay methods described herein, or similar assays, may be used for quantitating circulating kallikrein polypeptide levels in patients prior to treatment. Such assays may also be used for monitoring throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters, such as serum kallikrein polypeptides.

The invention further provides vaccines formulated to contain kallikrein polypeptides or fragments 35 thereof. The use in anti-cancer therapy of tumor antigens in a vaccine for generating humoral and cell-mediated immunity is well known and, for example, has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63: 231-237; Fong et al., 1997, J. Immunol. 159: 3113-3117). These methods can be practiced by employing kallikrein polypeptides, or fragments thereof, or polynucleotides and recombinant vectors capable of expressing and appropriately presenting the kallikrein immunogens.

By way of example, viral gene delivery systems may be used to deliver polynucleotides encoding kallikrein polypeptides. Various viral gene delivery systems which can be used in the practice of this aspect of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbis virus (Restifo, 1996, *Curr. Opin. Immunol.* 8: 658-663). Non-viral delivery systems may also be employed by using naked DNA encoding kallikrein polypeptides, or fragments thereof introduced into the patient (e.g., intramuscularly) to induce an anti-tumor response.

Various *ex vivo* strategies may also be employed. One approach involves the use of cells to present kallikrein antigens to a patient's immune system. For example, autologous dendritic cells which express MHC class I and II, may be pulsed with kallikrein polypeptides, or peptides thereof that are capable of binding to MHC molecules, to thereby stimulate renal cell carcinoma patients' immune systems (See, for example, Tjoa et al., 1996, *Prostate* 28: 65-69; Murphy et al., 1996, *Prostate* 29: 371-380).

Anti-idiotypic antibodies specific for kallikrein polypeptides can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing the polypeptides. The generation of anti-idiotypic antibodies is well known in the art and can readily be adapted to generate anti-idiotypic antibodies that mimic an epitope on a kallikrein polypeptide (see, for example, Wagner et al., 1997, *Hybridoma* 16: 33-40; Foon et al., 1995, *J Clin Invest* 96: 334-342; Herlyn et al., 1996, *Cancer Immunol Immunother* 43: 65-76). Such antibodies can be used in anti-idiotypic therapy as presently practiced with other anti-idiotypic antibodies directed against tumor antigens.

Genetic immunization methods may be utilized to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing kallikrein polypeptides. Constructs comprising DNA encoding kallikrein polypeptides/immunogens and appropriate regulatory sequences may be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded kallikrein polypeptides/immunogens. The polypeptides/immunogens may be expressed as cell surface proteins or be secreted. Expression of the polypeptides/immunogens results in the generation of prophylactic or therapeutic humoral and cellular immunity against the cancer. Various prophylactic and therapeutic genetic immunization techniques known in the art may be used.

The invention further provides methods for inhibiting cellular activity (e.g., cell proliferation, activation, or propagation) of a cell expressing kallikrein polypeptides. This method comprises reacting immunoconjugates of the invention (e.g., a heterogeneous or homogenous mixture) with the cell so that the kallikrein polypeptides form a complex with the immunoconjugates. A subject with a neoplastic or preneoplastic condition can be treated when the inhibition of cellular activity results in cell death.

In another aspect, the invention provides methods for selectively inhibiting a cell expressing kallikrein polypeptides by reacting a combination of the immunoconjugates of the invention with the cell in an amount sufficient to inhibit the cell. Amounts include those that are sufficient to kill the cell or sufficient to inhibit cell growth or proliferation.

Vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used to deliver polynucleotides encoding kallikrein polypeptides to a targeted organ, tissue, or cell population. Methods well known to those skilled in the art may be used to construct

recombinant vectors that will express antisense nucleic acid molecules for kallikrein polypeptides. (See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra)).

Genes encoding kallikrein polypeptides can be turned off by transfecting a cell or tissue with vectors that express high levels of a desired kallikrein polypeptide-encoding fragments. Such constructs can 5 inundate cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases.

Modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the regulatory regions of genes encoding kallikrein polypeptides, i.e., the promoters, enhancers, and 10 introns. Preferably, oligonucleotides are derived from the transcription initiation site, e.g. between -10 and +10 regions of the leader sequence. The antisense molecules may also be designed so that they block translation of mRNA by preventing the transcript from binding to ribosomes. Inhibition may also be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the 15 double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Therapeutic advances using triplex DNA were reviewed by Gee J E et al (In: Huber B E and B I Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco N.Y.).

Ribozymes are enzymatic RNA molecules that catalyze the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by 20 endonucleolytic cleavage. The invention therefore contemplates engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding kallikrein polypeptides.

Specific ribozyme cleavage sites within any potential RNA target may initially be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, 25 GUU and GUC. Once the sites are identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be determined by testing accessibility to hybridization with complementary oligonucleotides using 30 ribonuclease protection assays.

Methods for introducing vectors into cells or tissues include those methods discussed herein and 30 which are suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors may be introduced into stem cells obtained from a patient and clonally propagated for autologous transplant into the same patient (See U.S. Pat. Nos. 5,399,493 and 5,437,994). Delivery by transfection and by liposome are well known in the art.

Kallikrein polypeptides and polynucleotides encoding the polypeptides, and fragments thereof, 35 antibodies, and/or agents identified using a method of the invention, or combinations thereof, may be used in the treatment of renal cell carcinoma or diseases, conditions or syndromes associated with renal cell carcinoma, in a subject. The kallikrein polypeptides, polynucleotides, and agents may be formulated into compositions for administration to subjects suffering from renal cell carcinoma. Therefore, the present invention also relates to a composition comprising kallikrein polypeptides, or polynucleotides encoding the

- 30 -

polypeptides, or a fragment thereof, or an agent identified using a method of the invention, and a pharmaceutically acceptable carrier, excipient or diluent. A method for treating or preventing renal cell carcinoma in a subject is also provided comprising administering to a patient in need thereof, kallikrein polypeptides, or polynucleotides encoding the polypeptides, an agent identified in accordance with a method 5 of the invention, or a composition of the invention.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the substance from the action of enzymes, acids and other natural conditions that may inactivate the 10 substance.

The compositions described herein can be prepared by *per se* known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's 15 Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the active substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The compositions are indicated as therapeutic agents either alone or in conjunction with other 20 therapeutic agents or other forms of treatment (e.g. chemotherapy or radiotherapy). The compositions of the invention may be administered concurrently, separately, or sequentially with other therapeutic agents or therapies.

The following non-limiting examples are illustrative of the present invention:

Example 1

25 Human kallikreins 5, 6, 10, and 11 (hK5, /6/10/11) are expressed by many normal tissues and it has been suggested that they may represent candidate cancer diagnostic/prognostic markers. Renal cell carcinoma (RCC) is characterized by unpredictable outcome, despite the use of conventional prognostic factors. The immunohistochemical expression (IE) and the predictive value of the above kallikreins was evaluated in RCC. Included in the study were 95 patients who underwent radical nephrectomy for RCC. The 30 median follow-up was 60 (1-180) months. Fifty seven of the 95 RCC cases were immunostained for hK5, 70/95 for hK6, 70/95 for hK10, and 69/95 for hK11, respectively. The immunohistochemical method of streptavidin-biotin-peroxidase using anti-hK5, /6/10/11 monoclonal and polyclonal antibodies was performed. The IE of all kallikreins was correlated with tumor size, histological type, histological malignancy, mitotic index, and pathological stage. The Fuhrman 4-scale grading system was used for the 35 determination of the histological malignancy. For statistical analysis, four grades were collapsed into two and RCC cases were categorized as low and high malignant (LM and HM) respectively. Statistical analysis included Pearson Chi-square and Kruskal Wallis tests. Survival data were analyzed using Kaplan-Meier and Cox regression analysis. A Pvalue < 0.05 was considered significant. In the normal (adjacent to tumor) renal parenchyma, the epithelium of the urinary tubuli showed a cytoplasmic IE of all kallikreins. In RCC, their IE

was decreased: 33/57 cases (58%) were positive for hK5, 27/70 (39%) for hK6, 46/70 (66%) for hK10 and 32/69 (46%) for hK11, respectively. A statistically significant positive correlation was observed among the IE of all kallikreins. HM-RCC expressed all kallikreins in a higher percentage than LM-RCC, but a statistically significant difference was observed only in the case of hK6 and hK10 (55% vs. 27%, p= 0.016
5 and 79% vs. 56%, p=0.044 respectively). Hk6 and hK11 showed a positive correlation with pathological stage: hK6 with both Robson and TNM 1997 staging systems (p=0.010 and p=0.017 respectively), and hK11 only with the Robson staging system (p=0.045). In both the Kaplan-Meier and the univariate Cox regression analysis, hK6 IE showed a negative correlation with disease survival (p=0.05 and p=0.038 respectively). In univariate analysis, nuclear grade, Robson and TNM staging systems correlated with disease survival as
10 well. However, in the multivariate analysis, TNM staging system was the only independent prognostic factor. In conclusion, although the IE of hK5/6/10/11 is down-regulated in RCC, tumors of high grade and/or advanced stage express one or more of the above kallikreins in a higher percentage. It seems that hK6 may significantly contribute to information in predicting poor disease outcome for RCC.

15 The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within
20 the scope of the appended claims.

25 All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the domains, cell lines, vectors, methodologies etc. which are reported therein which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

30 It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Below full citations are set out for the references referred to in the specification.

- 32 -

Table 1

Kallikrein Polypeptide	Kallikrein Nucleic Acid Designation	GenBank Accession No.
Kallikrein 5	KLK5	AAF03101, AF135028 (mRNA join 2101..2131, 2210..2293, 4762..5023, 5763..6019, 6105..6238, 11092..11570) (CDS join 2221..2293, 4762..5023, 5763..6019, 6105..6238, 11092..11247), AF168768 (CDS 170..1051)
Kallikrein 6	KLK6	AFB66483, AF013988 (CDS 174..881), AF149289 (CDS 3567..3606, 4346..4502, 8211..8369, 9791..9927, 11805..11954) (mRNA join 2001..2185, 3084..3135, 3559..3606, 4346..4502, 8122..8369, 9791..9927, 11805..11957), HSU62801 (CDS 246..980)
Kallikrein 10	KLK10	AAC14266, AF055481 (CDS 614..701, 2455..2635, 3589..3863, 4195..4328, 4793..4945) (mRNA join 48..120, 605..701, 2455..2635, 3589..3863, 4195..4328, 4793..5474), NM_002776 (CDS 220..1050)
Kallikrein 11	KLK11	BAA33404, AAD47815, AB012917 (CDS 26..874), AF164623 (CDS 4224..4263, 5061..5217, 5545..5810, 6627..6727..6763, 7158..7307) (mRNA join 2312..2398, 4189..4263, 5061..5217, 5545..5810, 6627..6763, 7158..7310)

We Claim:

1. A method for detecting kallikrein polypeptides or polynucleotides encoding kallikrein polypeptides that are associated with renal cell carcinoma in a patient comprising:
 - 5 (a) taking a sample from a patient;
 - (b) detecting or identifying in the sample one or more kallikrein polypeptides or polynucleotides encoding the kallikrein polypeptides wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 ; and
 - 10 (c) comparing the detected amount with an amount detected for a standard.
2. A method for detecting kallikrein polypeptides associated with renal cell carcinoma in a patient comprising:
 - (a) obtaining a sample from a patient;
 - (b) detecting in the sample one or more kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
 - 15 (c) comparing the detected amounts with amounts detected for a standard.
3. A method for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting in a sample from the subject one or more kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein.
4. A method as claimed in claim 1, 2 or 3 wherein the kallikrein polypeptides are detected using antibodies that bind to the kallikrein polypeptides or parts thereof
5. A method of detecting renal cell carcinoma in a patient, the method comprising comparing:
 - 25 (a) levels of kallikrein polypeptides in a sample from the patient, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
 - (b) normal levels of expression of the kallikrein polypeptides in a control sample, wherein a significant difference in levels of kallikrein polypeptides, relative to the corresponding normal levels, is indicative of renal cell carcinoma.
- 30 6. A method of any proceeding claim where the levels of kallikrein polypeptides are higher than normal levels and are indicative of advance disease and/or poor prognosis.
7. A method for monitoring the progression of renal cell carcinoma in a patient, the method comprising: (a) detecting in a sample from the patient at a first time point, kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; (b) repeating step (a) at a subsequent point in time; and (c) comparing levels detected in steps (a) and (b), and thereby monitoring the progression of renal cell carcinoma.

8. A method for determining in a patient whether renal cell carcinoma has metastasized or is likely to metastasize in the future, the method comprising comparing (a) levels of kallikrein polypeptides, in a patient sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) normal levels or non-metastatic levels of the kallikrein polypeptides, in a control sample wherein a significant difference between the levels of expression in the patient sample and the normal levels or non-metastatic levels is an indication that the renal cell carcinoma has metastasized.
5
9. A method for assessing the aggressiveness or indolence of renal cell carcinoma comprising comparing: (a) levels of expression of kallikrein polypeptides, in a patient sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) normal levels of expression of the kallikrein polypeptides, in a control sample, wherein a significant difference between the levels in the patient sample and normal levels is an indication that the cancer is aggressive or indolent.
10
10. A method for diagnosing and monitoring renal cell carcinoma in a sample from a subject comprising isolating polynucleotides from the sample, and detecting in the sample polynucleotides encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein.
15
11. A method as claimed in claim 10 wherein significant differences in the levels of the polynucleotides in the sample compared to a control is indicative of disease, disease stage, stage, and/or prognosis.
20
12. A method for determining the presence or absence of renal cell carcinoma in a subject comprising: (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides encoding kallikrein polypeptides relative to a predetermined cut-off value, and therefrom determining the presence or absence of renal cell carcinoma in the subject.
25
13. A method as claimed in claim 12, wherein the nucleic acids are mRNA and the levels of nucleic acids are detected by polymerase chain reaction.
30
14. A method as claimed in claim 12, wherein the nucleic acids are mRNA and the amounts of mRNA are detected using a hybridization technique, employing oligonucleotide probes that hybridize to kallikrein polypeptides.
35
15. A method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, the method comprising comparing: (a) levels of kallikrein polypeptides, and/or polynucleotides encoding same in a first sample obtained from a patient and exposed to the test agent, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein polypeptides and/or polynucleotides encoding same in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of the kallikrein polypeptides and/or polynucleotides encoding same in the first sample,

relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting renal cell carcinoma in the patient.

16. A method of claim 15 wherein the first and second samples are portions of a single sample obtained from the patient.

5 17. A method of claim 15 wherein the first and second samples are portions of pooled samples obtained from the patient.

18. A method of assessing the efficacy of a therapy for inhibiting renal cell carcinoma in a patient, the method comprising comparing: (a) levels of kallikrein polypeptides and/or polynucleotides encoding same in a first sample obtained from the patient, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein polypeptides and/or polynucleotides encoding same in a second sample obtained from the patient following therapy, wherein a significant difference in the levels of expression of the kallikrein polypeptides and/or polynucleotides in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting renal cell carcinoma in the patient.

15 19. A method of selecting an agent for inhibiting renal cell carcinoma in a patient the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately exposing aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of kallikrein polypeptides and/or polynucleotides encoding same in each of the aliquots, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (d) selecting one of the test agents which alters the levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.

20. A method of inhibiting renal cell carcinoma in a patient, the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of kallikrein polypeptides and/or polynucleotides encoding same in each of the aliquots, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (d) administering to the patient at least one of the test agents which alters the levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.

25 30 35 21. A method of assessing the renal cell carcinoma cell carcinogenic potential of a test compound, the method comprising: (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and (b) comparing expression of kallikrein polypeptides and/or polynucleotides encoding same, in each of the aliquots, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and wherein a significant difference in levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot maintained in the presence of the test compound,

relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses renal cell carcinoma cell carcinogenic potential.

22. An *in vivo* method for imaging renal cell carcinoma comprising:
 - (a) injecting a patient with agents that bind to kallikrein polypeptides, the agents carrying labels for imaging the renal cell carcinoma, and wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11;
 - (b) allowing the agents to incubate *in vivo* and bind to the kallikrein polypeptides; and
 - (c) detecting the presence of the labels localized to the renal cell carcinoma.
- 5 23. A method of inhibiting renal cell carcinoma in a patient at risk for developing renal cell carcinoma, the method comprising inhibiting expression of genes encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11.
- 10 24. A method of any preceding claim comprising at least two of the kallikrein polypeptides.
- 15 25. A method of any preceding claim comprising at least three of the kallikrein polypeptides.
26. A method of claim 22 where the kallikrein polypeptides are kallikrein 6 and kallikrein 11.
27. A method of any preceding claim wherein the patient sample comprises serum obtained from the patient.
28. A kit for carrying out a method as claimed in any preceding claim.
- 20 29. A kit for assessing whether a patient is afflicted with renal cell carcinoma, the kit comprising reagents that specifically bind with kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.
30. 30. A kit for assessing the suitability of each of a plurality of agents for inhibiting renal cell carcinoma in a patient, the kit comprising: (a) the plurality of agents; and (b) reagents for detecting kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.
- 25 31. A kit as claimed in claim 28 or 29 wherein the reagents are antibodies that specifically bind with protein or protein fragments corresponding to kallikrein polypeptides.

Sequence Listing**SEQ ID NO. 1**

hk5 amino acid

5

MATARPPWMWVLCALITALLLGVTTEHVLANNNDVSCDHPNSNTVPSGSNQDLGAGAGEDARSDDSSRIINGSD
 CDMHTQPWQAALLLRPNQLYCGAVLVHPQWLTAAHCRKKVFRVRLGHYSILSPVYESGQQMFGGVKSIPH
 YSHPGHSNDLMLIKLNRRIRPTKDVRPINVSSHCPASAGTKCLVSGWGTKSPQVHFPKVLQCLNI SVLSQKR
 CEDAYPRQIDDTMFCAGDKAGRDSQCQGDGGPVVCNGSLQGLVSGDYPCARPNRPGVYTNLCKFTKWIQET
 10 IQANS

SEQ ID NO. 2

KLK5 CDS

ggtgtctgtg cgtcctgcac ccacatctt ctctgtcccc tccttgccct gtctggaggc
 15 tgctagactc ctatcttctg aattctatag tgcctgggtc tcagcgcagt gccgatgggt
 gcccgtcctt gtgggttcctc tctacttggg gaaatcagggt gcagcggcca tggctacagc
 aagacccccc tggatgtggg tgctctgtgc tctgtatcaca gccttgcctt tgggggtcac
 agagcatgtt ctcggcaaca atgatgtt ctgtgaccac ccctctaaca ccgtgcccctc
 tgggagcaac caggacctgg gagctggggc cggggaaagc gcccggtcgg atgacagcag
 20 cagccgcatac atcaatggat ccgactgcga tatgcacacc cagccgtggc agggccgcgt
 gttgctaagg cccaaaccagc tctactgcgg ggcgggttg gtgcattcac agtggctgt
 cacggccgccc cactgcagga agaaagtttt cagagtccgt ctggccact actccctgtc
 accagtttat gaatctggc agcagatgtt ccaggggtc aaatccatcc cccaccctgg
 25 ctactccac cctggccact ctaacgcact catgctcatc aaactgaaca gaagaattcg
 tcccactaaa gatgtcagac ccatcaacgt ctcctctcat tgccctctg ctgggacaaa
 gtgcttgggt tctggctggg ggacaaccaa gagccccaa gtgcacttcc ctaaggtcct
 ccagtgcctt aatatcagcg tgctaagtca gaaaagggtgc gaggatgtt acccgagaca
 gatagatgac accatgttct ggcgcgggtga caaagcagggt agagactctt gccagggtga
 30 ttctgggggg cctgtggct gcaatggctc cctgcaggga ctgtgttccct gggagagatta
 cccttgtgcc cggcccaaca gaccgggtgt ctacacgaac ctctgcaagt tcaccaagt
 gatccaggaa accatccagg ccaactctg agtcatccca ggactcagca caccggcata
 cccacctgtt gcagggacag ccctgacact ccttcagac cctcatttcc tccagagat
 gttgagaatg ttcatctctc cagccccctga ccccatgtct cttggactca gggctgtt
 35 ccccccacatt gggctgaccg tgcgtctcta gttgaaccct gggacaatt tccaaaactg
 tccagggcgg ggggtgcgtc tcaatctccc tggggcactt tcattcctcaa gctcaggccc
 catcccttct ctgcagctt gacccaaatt tagtcccaga aataaaactga gaagtggaaa
 aaaaaaaaaa

40 SEQ ID NO. 3

KLK5 nucleic acid

ggggcccagag tgaaggcaag agaaggagtt gagagctccc tctgcaaagt ggcttgagtc
 tcccctgcct aaaatgcagg gagagggagg cagaaagaca gggaaagagga aggggtgggg
 45 aagaaaagaga gagagagaga gagacagaat aacacaacta cagaaacaca gagagaacac
 acagagagcc tgggacacag ggacacacag agttagagag aaaagagaag atagagaaag
 acacaaaatgg agacacacag gtgtaaagaa agagagatta acagagtccc agatacacgc
 aaaggggcag aagcacaatgg ttccagggtgg tgcgtatgat catcttcttt tttttttttt
 tttttttttt tttttgagac ggagtctcgc tctgtcgccc aggctggagt gcagtggcgg
 50 gatctcggtt cactgcaagc tccgcctccc ggggtcacgc cattctcctg cctcagcctc
 ccaagtagct gggactacag gcccggcca ctacgcccgg ctaattttt tgattttta
 gtagagacgg ggttccaccc ttttagccgg gatggcctcg atctcctgac ctcgtgatcc
 gccccctcg gcctcccaaa gtgctggat tacaggcgtg agccaccgcg cccggccatg
 atcatctctc tgactatgtt gatgtgacaa gtacctaag ccatcagact ctaccctta
 55 aatatgcagt ttgggccagg caccgtggct catgcctgta attccagcac ttgggaggc
 agagggtgggt gaatcacttg aggccaggag tttgagacca gcttggccaa catggtaaa

ctctgtcttt actaaaaaaaaaaaaaaa aaaaaaaaaatc agccgggtgt cgtggggcac
 acctgtatc ccagctatgc tggaggctga ggcacgagag tcacttgaac cctggaggcg
 gaggttgcag tggccgaga tcacatcacc gcccctccagc ctgggcgaca gagcaagact
 ctgtctcaaa taaataaata aacaaacaa caagcagtt gttgtacctt agttatatct
 5 aaaaaaaaaaa tgctgtcaac aaatagagca gaagtgaaat aaaggaaaat aaatgggcca
 agaactctaa ggtatattt acaaattcatt cagaacctt aaaaaagaaa gaatcacaga
 ggcatagaaa gacaggggagg aacagggaga cagaaacacc tggcccaaa ggagaacaaa
 acaaggctcc taagacagac aggaggagag agagagagag tgagtggag acagacagag
 aaaaagacag agagagagag acagagacag agagacagag aggcgagagg gatagaaa
 10 gagagagggg tggagagaga cacgagat tgagagagac tcagaaagat agccgaggga
 gaaccacaga gagatggaa aagactctga aaaaaacc aagacaaa tgaaagagg
 agtactcgagg gtgaacacagc agtgggtgaa tgacaaaatc gcaagaaaga aagaagcaa
 tccaggcgcc aagaatagtg acccagagtt ggtgagaagc cagatcctt aggctgggg
 15 aggcacggaa ggggctggcc tggctccgg agacccctcc ccattctcc ggccaggag
 gttagggagtg acattccgg a cttgggtggg ggtgctctgg gggtgagat agggggagca
 ggaggagcta ttgtctaaggc ccgataggca cctcattgc cggaaatgtg ccccaggag
 cagtgggtgg ttataactca gggccgtgc ccagagccca ggaggaggca gtggccagga
 aggcacaggc ctgagaagtc tgcggctgag ctgggagca atccccacc ccctacctgg
 20 gggacacgggc aagttagacc tggtgagggt ggctcagcag gcagggagg agaggtgtct
 gtgcgtctg caccacatc ttctctgtc ccctccttc cctgtcttga ggctgctaga
 ctcctatctt ctgaattcta tagtgcctgg gtctcagcgc agtgcgtat gtggccctgtc
 cttgtgggtc ctctctaccc gggaaataa ggtagggag ggaggggaag tgggttaagg
 gctccccgga tcgcctggc ctcacccatc tctgacattc cccatccagg tgcagcggcc
 atggctacag caagaccccc ctggatgtgg gtgcgtctgt ctctgatcac agccttgctt
 25 ctgggggtca caggtaacca gaactctggg gtggggagggt tggggatttgg gggactgt
 ctctgcggca ctagagcgc tgcgtccctgg ggaactgtgt gggctggc atgactccgg
 gaccgggtga atgtgagtct ctgtctgtac ttgtgggtgt gcatcgatgtat gtggccctgt
 gactgcccacg gtgtgtgtcg gggaggggg tgcctttcc catatcaagg tgcgtccgg
 caggtggcac tgaccctttg aggctgtgt tgggttttg tggattgtgt tgcatattaag
 30 attgtgtgtg gctccacagc tgcgtgggtg aatgcgtatc gcaactggggg tggactgt
 gtgtttggct gtgtgtgggt acttggcatt gtatactact gcaaggatct gcaacttccgt
 tccctgaggt cccgggatttgc cgtcaacaa aagtggcat caccatggaa agctgtgact
 gtgtgtgtct tgcaaggcgat tatgtgatgg tggctgatgt tgacgtttagt gatggccgt
 tttgtgaccg tgcgtactacc tgaagctctg tgggtgggtg actgtatgtg actgtgtgt
 35 tctgtgtgag gccgtgtaaa tgctactgtg tgggtatgg tgcaactgtg tgcagctgtg
 ttctgtctct gcctggaggg atagagggtg cagggttagc tatctctggg agatgggtgc
 caggtgactg acttgcgtg tgcgtctgtg tgcaagaagag tatgtggcag tctgaacatc
 tgtgcacaca cggcatctgt gctgtggcaact gagacactgt ggtgagggt gtgcgtatccc
 gctaggctgc cggggagcgt gtgtacctgg agacagagct gtatgttagt tgcacctgt
 40 gaggcaacat gggcgtgtct gcagaactgc gtgcgtgtt ggctgttact gctgtgtgc
 gcgtgggtct tgggtgagtt tcgtgaatga tgggtgtgcc agggccatca gcaagggtaa
 gaaccagcc gggcgcgggt gctcacccct gtaatcccag ccctttggg ggcggaggca
 ggcggatcac ctgagggtcg gagatcgagg ccagcctgac caacatggag aacccctgt
 ctactaaaaaa tacaaaaaaat tagctgtgt ggtggcgcgt gcctgtatc ccagctactc
 45 gggagactgg ggcagaaaaaa tcgcttgaac cggggagggt gagggttgcgg tgaggccgaga
 tcgcgcatt gcactccagc ctggcaaca agacgaaac tccgtctcg aaaaaaaaaaa
 gaaaaaaaaaa aggtaagaa ccagtgaatg ggcacgggag gactgtatgtt ggagtggggc
 atgcatgtatc tctgttagtc tgggtgtgttggaggat tgacaggatt gagaaggcat
 gtttctactt gagaattcag aaaccttaggc ctgtcttcc cctccatgtg gccccctaag
 50 ctgagccctt ctttctgtt cctgtttcg gaacccttagc tccgtctcg agtctgacc
 ccacccctt ccacca cgcggcttagg ccagactcta gtggaccccg cctaaggcca
 cacccttgc ggcaggctc cacccttcat tctgtgggtt cctcttagaa ccccttcaa
 agtcagagct tttttttttt ttttttttgc gacagtcttgc ctctcttcc caggctggag
 tgcgtggcg tgatctcgcc tcactgtcaac ctgtcttcc cagggttcaag tgattctcg
 55 gcctccaccc cctgagtagc tgggattaca ggtgcgcgccc accacggctg gctaattttt
 gtgtctttag tagagacagg gttcacctt gttggccagg ctggtctcaa actcccaacc
 tcaggtgatc cgcacccaccc ggcctcccg agtgcgtgggg ttacaggcgt gagccaccgc
 ccccaagccca aagtcaagc tctttatagg agactctaact atgttaaccct gaccctggcc
 ctaactaagt caattccaaa ccccttctcg cttccagcccc tgaccctact cactgaggcc

tgaccccact tcttgagacc agttccatcc ctaaagccct ggtctccctc ccatccccag
gctccagccc ccacagcttt ggcactaccc ctgagcttg ccaggaatcc tgtacccaat
tttaccctca catgtatcc tagccaattc cagaatctg tgaggtccag ttagagtcca
5 gtaaccctac ctgagcctgg gctctgtct tgagcttgg cctgggttg agaggtgcc
ctcttattct ccaggccctg cccctgcccc cttagcatgt cagacaccca ccctctagct
ggtctggct cttgagtctg aaacccaccc ccagcccaag ccccgccctc gagccccgccc
caaccacatt tccgttccca gagcatttc tcgccaacaa tgatgttcc tgtgaccacc
cctctaacac cgtgccctct gggagcaacc aggacctggg agctggggcc gggaaagacg
cccggtcgga tgacagcagc agccgcatac tcaatggatc ctagtgcgt atgcacaccc
10 agccgtggca ggcgcgcgtg ttgctaaaggc ccaaccagct ctagtgcggg gcggtgttgg
tgcattccaca gtggctgtc acggccccc actgcaggaa gaagtgaatg ggagttccaa
gaggagggtt ggtggggacg gggaaatggg ggtgggggtt gggaaatgggg ggtgggggtt
tcatcgaggtt gagggtctgtt gggggacgggg aagtgggggtt ggggggttca tgaaaggtga
gggttgggtt ggtatgggtt gggatgtttt gacaggagga ggtcagttt gggataggac
15 taaggatgga gttttgcggg ggagcaaggt gggaggatga gtttggagag gggagatgtt
tgtggtaggg aatgggaagg agccaaggat gggttggatt tgggtttagg agcatatatt
tgttgaatgg tttggatgg aggttggattt gggattggct ttagaattgg ggggtgggtga
aaatcggtt ggggtggaaa tgaagatagc atggagatag gtttggatgg gggagcagat
atagaatgaa ggtatgggtt tggatgtttt ggtgggggtt gggatgggtt gggatgggtt
20 tgagaatgca tatggtgatg gcttctgggt agggaaagaa ttaggggttgg gaaatgggtt
ggtttggaaat tttgactggg atggggacag gcatgggatt ggagaccaag aggaggttga
ggatggttt gggaccgggg gtggggatgg gggggggctt gggggctt gttgggggtt
gattggcgtt ggacgtggag atagagatca ggggttgggg ttagctgccc catcttcctc
agagtttca gagtccgtct cggccactac tccctgtcac
25 cagatgttcc agggggtcaa atccatcccc caccctggct actccaccc tggccactct
aacgaccta tgcctatcaa actgaacaga agaattcgtc ccactaaaga tgcagacacc
atcaacgtct cctcttattt tccctctgtc gggacaaatg gcttgggttgc tggctgggg
acaaccaaga gcccccaagg tgagtgttca ggttcttctt gataccgacc catctctgcc
gccttccatc ttttccact tctcattttt ttcctgttgc
30 cctccagtgcc ttgaatatca gctgtctaaag tcgaaaagg tgcgaggatg cttaaccggag
acagatagat gacaccatgt tctgcgcggg tgacaaagca ggttagagact cctccaggt
gaggacaccc ctctttttt ctcgttgc acgtacataca cactgtgtc caactcggtt acatggagcg
tttggcaattt ctgagaatcc agcaatttgc aagacagtca ggaccctgt tctcacagag
ctcataccct agagtagtgg ttttttagt aaataatgtt gactgttcaatgggg
35 agtttttag tagccacatt aaaacagta aaaaaggctg ggcgcagtgg ctcacacactg
taatcccgac actttgggg gctgaggccg gcagatcacc tttggtcagg agtttgagac
tagcctggcc aacatggcgaa aactctgtct ctaaaaaaaaaa atacaaaaat tagcctggca
tggtggcggtt cgcctgtat ctcagctgtc caggaggccg agacacaaga atacttaaa
cccaggaggt ggaggttgcgat gttagctgtc atcgtgccat tcactccaa ctgggagaca
40 gagtgacact tttgtctcaa aaagaaaaaa aaaaacaagt aaaaagaaa caggtgaagt
taactttaat aacccaaatgt atcccaaata caatcatttca aaagtgtat taatataaaa
caattatgaa tgagataactt tacattttt tcttggggc atattaatgc tttgaaatgt
agtatatatg ttatgtctgc agcacatctc aattttgact agctacattt caggtgtca
gtagccacat gtggcttagca gttactgtat tggatggcac ggatctagag gaaagatca
45 gggctgtttt gtatgggttgc gcagggttgc cactgcataa agataccata tctaataagg
gcactccgtt ttacagatgt cagtttttgc agttttgcagg cgtgtgttag ttaagtgtct
tgtttcaaca aaatctgtaa tatgacagtt ttcttagcaag tgctggtaaa atatcttgag
gaaggaaatgg agaaatctgg tagttttt tacaagagaa tatttaatac agggattaa
ttgcaaaatgt gctggaaaggc ctggaggaac aaagttaaaa aataaaaaac tctgtgtca
50 agaaatctgca taaataggc aatttcagag agtggtaaag gttaaacccca aaataaaaca
tggtttttagt atagtaaaca ataaggccca atattcaaaa aggtggtcag gggagcctcc
ttggagaggtt ggcatttgcg cagagaatgg atgacacaaa gaagctaaac tcgtgaagt
taagggggaaa gaaaaggcac gtgcacccgc cctggggcgtt taaggaattt ggctgtattca
aagaagaaga gggaaaccaat gcaactggag aacaaaatgt gggcaacac tagaaatgt
55 cgctggaggtt gttaggcaggc gcgaatgttc tgcaagtatt tcttggtcac caacacag
cttccctatgt ttctaatggc agctgtatct ttgtggaaagc acagaattta aaatcaaact
gttacatcaa ccagcaccc tctctgtatt caggctccca agggatctag aaggacgtaa
gttaacaagc tctcatttgc aggtgtgtt tttcaacatgt agtttaggaag ctggggattc
aggagtactc cagtcctatg gctatgaaaaa gttttttttt aattgtacaa acctgacaaa

5	tgcaacacct	cccaagctct	ccccatttct	tctctgtgcc	ctgggtgtgg	gggggtgggg
	tgcgaggggg	aaaacttttta	acagaagaaa	gcacatctcg	gccgggcgtg	gtggctcaca
	cctgtaatcc	caacactttg	ggaggccgag	gcgggtggat	caactaggc	ggagatggag
	accatcctgg	ctgacacgggt	gaaaccctgt	ctctactaaa	aacacaaaaa	attagccggg
	cgtggtggca	ggcgcctgta	gtcccagcta	ctcgggaggc	tgagggcagga	aatggcctg
	aaccggggag	gcggaacttg	cagttagccg	aggttgcacc	actgcactcc	agctggggca
	acacagttag	actccgtctc	aaaaaaaaaa	aaagaaaaga	aaagaaaatca	catctcatc
	aagtggtggc	attttaaaact	atttagcctt	tctgtaggca	aggttagtat	cttgggtttt
10	cagacctcaa	ggtgtttttt	tgttgtttt	ttcataccgg	tgtgtggct	gggtgtggcc
	actaaaagct	acaagcaaga	aataataaca	actacaacaa	tactaatacc	aatagtataa
	aaataataagc	atctggctaa	ttgctggaca	ctgttttaag	tggttgcat	gcctcagctc
	attaactcat	ttacctgtta	ttattggccc	tattttacaa	acaaggagcc	aagctcaga
	gcagtttaact	aacagcctct	caaagaaaac	tctgcagaga	tattaaattt	aaaaaataat
	gagagaaaatt	aaaccacaag	aaagttgaaa	tttagaggt	caggcagcta	agcttggttt
	ctttgaaaaca	gtgtctgta	ctggaaaaaa	ggcaagtctt	ggcttccta	ataattgata
	ccaggactct	gtaattcata	ttttgcatgc	atgttaagtta	gaaatgaagc	cgggtgcaat
	ggcacatgcc	agtaatccca	gcactctggg	agactgaagt	ggyaagatca	cttggagctca
	ggagttcaag	accaggctgg	gcaactaaaa	ataaaaaaa	taaaaataact	aattgtttt
15	attttagtag	attttattca	taccacttac	atcattattt	tagatgtac	atatttattt
	ctttttttt	ctttttttt	cttttttgag	acggagtctc	gctctgtcac	ccaggctgg
	gtgcaatggc	accatattca	ctcaactgag	catgcgcctc	ctgggttcaa	gcatttttcc
	cacctcagcc	tcccaagtag	ctgggataac	aggcaccac	caccatgct	ggcttatttt
	ttttttccgt	agagatgggg	ttccaccat	ttggccaggc	tggcttga	ctctgacct
	ccagtgatct	gcctgcctcg	gcctcccaaa	ttgctggtat	tacagggtg	agccaccgtg
	cccaggtggg	agatagacat	ttctctctac	ctcaaacaga	gttccactca	agacttctt
	cattttcttc	ataaaatatta	gccgagtggc	tattttgcac	caggaatgt	tccaggtgt
	gtggatatgg	catcaggcaa	aacagaccaa	aaacttcctg	ccgcgtgac	ctcatgttcc
	ccaagtgaaa	gacaggcaat	aaagagatag	ataaaatatgt	agtaaattaa	aaaaaataat
20	aattagccgg	gtgtggtgcc	ttgcacctgt	agttccagct	acttggagg	ctgaggtggg
	agaattgcct	gagccaaac	gtttgaggct	gcccgtaaagcc	atgactgcac	tgctgcactc
	cagacagcag	cctgggtgac	aaagcaagac	gttttgcac	gaaagaaaaa	aaaaagagac
	gaagggagga	aggagagaga	aaggaaggaa	ggaaggagaa	agaaagggaa	gaaggagaaa
	gaaaggaagg	aaggaaggag	aaagaaagga	agaaagagaa	agaaagaaaa	agaaagaaaag
	aaagaagaaa	gaaaagagag	aggaaggaag	gaaagaagga	aaagagggaa	aaaaatgact
	gttgaagagc	agttagtatt	attataggag	ggttaattata	gggaggtatg	ggaaattgaa
	gacagggaaac	acaatttagt	ccaagcgaat	ggatttctat	tgggagtgtat	tctgccccta
	gaagacactg	gcaataccag	gagacatttt	tggtgtcac	aactatatgg	agggcatta
	ctggcaacta	atggatagat	gccaagtgt	ctgtcaaca	tgctatgtat	cacacggcag
25	gcctccacaa	caaaccatta	tccagcttca	gatgccac	gtgcccagat	cgaggaaccc
	tcatccaggg	gctgagaacc	gtatttttc	agaagggagg	tataaggatg	ggttgggtgg
	gaatggggaa	ggaagggtgt	tgtccagtaa	gagaataataag	gcctgcacag	gctggaggggg
	agagttagag	agaaaggggag	gcccggagat	acacgatgag	ggagacaggc	tggaacagaa
	agtagagacg	aagattcgag	atgtggagag	gaagggtcac	agacccccc	gaaatgtatgt
	gtggcaacaa	ggaatctgg	agaggaagat	ggagtggaga	gtgacaaatg	gggtctaaag
	aggtggggca	actacttgc	atgggtggctc	acgcctgtaa	tcccaacact	ttggaggctg
	ccgtctctac	aaaaaaaaata	caaaaaattta	gcccgggttg	ctggccaaca	tggtaaacc
	cagctacttg	ggaggctgag	gcaggagaat	tgcttgaacc	gtgatggaca	cctgttagtca
	gagctgaggt	cagggcactg	cgctccaacc	tggcaacag	cggggatgtt	aggcgcagt
30	aaaaaaaaagc	tggatttgg	gtgaaatatt	aataacattc	agtaagactc	catctcaaaa
	tgtgtctcca	tctctgtctt	tttctgcatt	tcttcatctc	tccctcttc	tccttttgc
	gtctgttccc	atctgcttct	ccatctatgg	gcatctctgg	tgtactttcc	atctctgtgt
	cccactttgc	cacatctctg	cctctctat	gcccccttt	gtctctcatg	tctccttct
	ggggggcctg	ttgtctgca	ttggctccctg	caggactcg	ctctcctgca	gggtgattct
	tgtcccggc	ccaaacagacc	gggtgtctac	acgaacctct	tgtcctgggg	agattaccct
	caggaaacca	tccaggccaa	ctcctgagtc	atcccaggac	gcaagttcac	caagtggatc
	cctgtctgca	ggacagccct	gacactccct	tcagaccctc	tcagcacac	ggcatcccc
	agaatgttca	tctctccago	ccctgaccctc	atgtctctg	attccttccc	agagatgttg
35	cacattggc	tgaccgtgtc	tctctagttg	aaccctggga	gactcaggg	ctgcttcccc

gggcgggggt tgcgtctcaa tctccctggg gcactttcat cctcaagctc agggcccatc
ccttctctgc agctctgacc caaatttagt cccagaaaata aactgagaag

5 **SEQ ID NO. 4**

hk6 amino acid

10 MKKLMVVILSLIAAAWEEEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTAHCKKPNLQVFL
GKHNLRQRESSQEQQSSVRAVIHPDYDAASHDQDIMALRLARPAKLSLEIQLPLERDCSANTTSCHILGWG
KTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNMLCAGDEKYGKDSCQGDGGPLVCGDHLRGLVSWGNI
PC GSKEKPGVYTNVCRYTNWIQKTIQAK

15 **SEQ ID NO. 5**15 **KLK6 nucleic acid**

CDS 147.. 881

20 gtcgaccacat gcgtccggct ggctggctcg ctctctccctg gggacacaga ggtccggcagg
cagcacacag agggacacctac gggcagctgt tccttccccc gactcaagaa tccccggagg
cccggaggcc tgcagcagga gcccgcattga agaagctgat ggtggtgctg agtctgattg
ctgcagccctg ggcagaggag cagaataagt tggtgcatgg cggaccctgc gacaagacat
ctcaccccta ccaagctgcc ctctacacccct cggccactt gctctgtggt gggtcctta
tccatccact gtgggtccctc acagctgccc actgcaaaaa accgaatctt caggtcttcc
tggggaaagca taacccctcg caaaggggaga gttcccagga gcagagtctt gtttccggg
ctgtgtatcca ccctgactat gatgccgcca gccatgacca ggacatcatg ctgttgcgccc
25 tggcacgccc agccaaactc tctgaactca tccagccct tcccctggag aggactgct
cagccaaacac caccagctgc cacatccctgg gctggggcaa gacagcagat ggtgatttcc
ctgacaccat ccagtgtgca tacatccacc tgggttcccg tgaggagtgt gaggatgcct
accctggcca gatcacccag aacatgttgt gtgtctggga tgagaagtac gggaggatt
cctgccaggg tgattctggg ggtccgctgg tatgtggaga ccacccctcgaa ggccttgggt
30 catggggtaa catccccctgt ggtacaaagg agaagccagg agtctacacc aacgtctgca
gatacacgaa ctggatccaa aaaaaccattt agggcaagtg accctgacat gtgacatcta
cctcccgacc taccacccca ctggctgtt ccagaacgtc tctcacctag accttgcctc
ccctcccttc ctgcccagct ctgaccctga tgcttaataa acgcagcgcac gtgagggtcc
tgattctccc tggtttacc ccagctccat ccttgcatca ctggggagga cgtgatgagt
35 gaggacttgg gtcctcggtc ttaccccccac cactaagaga atacagggaaaatcccttcta
ggcatctcct ctcggcaacc cttccacacg tttgatttct tcctgcagaggcccagccac
gtgtctggaa tcccagctcc gctgcttact gtcgggtgtcc cttggatgtacctttctt
caactgcagat ttctcacctg taagatgaag ataaggatga tacagtctccataaggcagt
ggctgttgg aagatttaag gtttcacacc tatgacatac atggaatagcacctggcca
40 ccatgcactc aataaagaat gaattttattt atgaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aggcgcccg c

40 **SEQ ID NO. 6**40 **KLK6 nucleic acid**

45 mRNA join(2001..2185,3084..3135,3559..3606,4346..4502,
8122..8369,9791..9927,11805..12483)

CDS join (3567..3606,4346..4502,8122..8369,9791..9927, 11805..11957)

50 acactaaaaa aatcttctga cttaaaaaaa aaagtatggt gattggaaaaa tgtaaatgtg
catgcgtgct tggcatcaca tttcattggc cagacttcc ctggatgcta aaggtccatca
aatgccaggc tggggggctg ggacttggc ccaaggggaga tggggaccca gggcacgtct
gtgagaggag gggcaagggtc agcacaaggc acaggaaggat ctctctgggg caagggatac
agagaacaga gggatcctgg tccaggtggg agaggtgcag ctctgagttg ggggttgggg
55 tgtgggtaca gagaggaagg gaccccccag agagaggagg cagaggata gggcctggtc
actgggttgt gcaacatcag acttgctgca tgtgaagata gcacgtcctg agaagaaggat

5 gctgagggtca gtggggacca aatgtgagag ggagcaccgg gagagtatac tgaataccga
 agtagtcitc atccctggag ttagtggggg tgcacaatgc aagatgacaa ttagattcaa
 tgcaagacaa agaaaagggt tggctggaa cagtggctca tgcctatggt cccagctc
 gggaaagactg aggcgggagg gtcgcitggag cccaggaggg ttgaggctgc cacagcaag
 10 gatcggtgca ctgcactcca gccttaggca cagaacaaga ccttgcitc aaagaaaaaa
 gaacttttt ttttaagttt cctgttagtgc ccagcccaag caggtgctga gccagacttc
 attccatatca ttgtccctat tacgcagtgta cttccccc ctcatttctc tccactctgc
 cacgcacac ccctccaccc ccagccata ccaaccaccc caaccactgc ctgtggttc
 ccatgtgcac ccaggccagg cattttcacg gccttc ctcgcaccc ctgacactcg cctggctc
 15 ctttcttaggc ccaagttcaa agacaccc ctaaatcc ctagatccct ctgctactgc
 ccagcaccac catcttatca cagcccaac tcgttcccaa gtgcctcccg atttctgttt
 aactccatgc ctctcgctgt gtgtccgc ctcataatac agtctcaag tccttccca
 tcctgttagc ttccatcg ctcggaaatc atccccctaa cttcctgggg aaactgactc
 ccttctgggc acacacagtg ctacccccc gggaaatctaa gaagagaccc aggagaagat
 20 aagcacggag agtcagagaa tcaaggggaa agaaaggagg agaggccggg cacagtggct
 cacacctgta atccagcact ttgggagggc aagggtgggt gatcacctga ggtcaggagt
 ttgagaccag cctggccaaat atggtaaac ctcttc ctaaaaatc aaaaaacatt
 tagccggggcg tgggtgggtgg tgcctgttaat cccagctact tgggaagctg aggaggaga
 actgcttcaa ctcaggaggc ggagggttgc gtgaactgag atcacaccac tgactcc
 25 cctgagtgc agagcaagac tccgtcaaaa aaaaagaaaag aaagaaaagaa aagaaggaaag
 gaaagaaaaga aggaaggaaag gaaggggagga agggagagag gaagggagag aggaaggag
 agagagaaaa aaagaggggag agagacacaa atacagagac tgagatggg gagagagaga
 gatggaaagct ccctccccc catggccagg gagacagatg gagcaagaga cctcagggt
 gggcagactt ggaggagaag gaccaggagg atgtggagtg ccgaaatctc cagtcagg
 30 caggtgggca gtcagagact gcaaaggagg actgtcagac agggacaaaa ggaagccatt
 gatgttaaccg ccctccccc tggccgcgg aagagaggtt gaggccggag ctgtggag
 catggcactg ggggtgtgg aggccgacaa agcccgattt tccctggcc ctttccccat
 cgcgcctggg cctgtcccc agccccggggc agggccgggg gccagtggt tgacacacgc
 ttagtgc tccccgggt gctggctcgc tcttcctgg ggacacagag gtccgcaggc
 35 agcacacaga gggacactac ggcagggtg tgagtccacc caacccgact gaaccc
 aggctgcttc ccagtgcggg agggctctag agcccgagt gaggccctgc aggtccctgg
 gtggcacaga gagtgtggg ggtgcaggga ggcctgggc accatctgct tgccccagag
 gccggaaattt gtctcagac acttttttc tccaaaaccc ggaggtctaa ggactgagcc
 gactagaact tcctctgcct cagattcagg ccccaagcccc tccctccca gaccaggag
 40 ttttaggtcct agccctcct ccctcagacc caggagtcca agttccacc tcctcc
 gactcaggag tccaggcccc cagcccccc tccctcagac ccaggagtcc aagttctcac
 ctccctccctc agacccagga gtccaggccc caagcccccc tccctcaga cgaagg
 caggccccca gcccctccctc cctcagactc aggagtccag gcccccaagc ccctcc
 tcagaccctc gagtccaggc cctcactgca ctcaggacc agtgctccct tcctggagg
 45 cctggtcagg ggtcaccaag agcagagcgt gggggccggga ggaatgtgtg tggagg
 gggtaaggag gaaaagggtg tagccagtt cctggctcag ggacctgaga gacagg
 aaaaggacgt tccagaagca tctggggaca gaaccagcc tttccaggaa ggcctgg
 ctgggggtgt gtgtctggc gtccctgcag ccctgggtc tgcggccct gctcc
 ctggctctg ccactgcatac tgagtgtctt ctctccctac ggctcccccc atttcta
 50 ctttctgcct cctcgctc aagctgttcc ttccccccgac tcaagaatcc cccggagg
 ggaggccctgc agcagggtgag atcacagacca tcacagaacc tgccgggtgg gcccc
 tggccatttc gcacagagcc aggctccggag gaaaactccc atacagagga agaac
 gccccccat gttaaccctc tccctgcac aggaaggcaa atcagtccc aagaaa
 aaagatctaa tcagaatctc accatgggtt actggaccag tggacgttagt tgaatt
 ttggcactgt tttctggat cctcttggaa gatgtgggtc gggaggaaat aaatcagg
 gtagatggg aaggacagag gtcaaggcag gagaccatag caggccagga aggaagg
 ggtgcagag ggacccagaca gagggtggg ggggggtcg aggactgac taatgg
 tggcttcc cctctcagga gcccgcatac agaagctgtat ggtgggtc agtctgatt
 ctgcagggtgg gggaaaggggca tttggatggg ggaggcttgc agacagggtt
 55 atggagaaga ggctggatt gggatgggg atatgcacag ggttgggtt gggagctt
 gaaatggaga agacgttggg gattaggctt agggggggaa atacagatag ggagg
 gggagggtgg tttgaagata tgagggtttt ggggggggtt ggctttaggg atgggg
 aaacatagaa gaggtaggag ttaggttggaa aagttggaga gagcccgaaa ataggg
 cagttgggtt tgtaatggga atggggtaag tttggagtg gaaatacaga gaagctttt

ttttttgaga cagggtctca ctctgtcacc caggctggag ttagtggca tgatccatag
 ttcactgcag acttgaactc ttgggtctca agtaccctc ccacccatc ctcctaagta
 gctgggacta caggcgatg ccaccatacc ctgtaattt gtgtgtgtgt gtgtgtgt
 gtgtgtgtgt gtgtgtgtgg agatgaggtc tcactgtgtt accgaggctg gtctcaaact
 5 cctgggctca agcgatcctc ctgcctcagc tggattaca ggcataagcc actgcacctg
 accaatctt actggagttc atgttggggg ggtgcgcctt ggttctcca gaactccct
 ctgactcaga tcttctctcc ctgcgcctgg gcagaggagc agaataagtt ggtgcacggc
 ggaccctgcg acaagacatc tcaccctac caagctgccc tctacaccctc gggccactt
 ctctgtgggt gggcttataa 10 ccattccactg tgggtctca cagctgccc ctgcaaaaaaa
 ccgtgagttc acatgtaaa tgaacacggc atgcactga accctgaggg tgccttatag
 atgtcagcga ggaggtgaca taggcattccc cccatccca gcacgaggcc atctgatagc
 caggtgcatt cggctgtgc ttaatttgcg acttaatgtg tgccaggccc tgcgggcata
 gcagtggaaa aaaaaataaa aaaaaagaaaaa caaaaaaaaaa caagcaaaat tgcgttttc
 15 ctgaacttac ttttaatgg gggaaatttggc tcatttgggg acctgcaggc cgtgatggc
 atttggattt aattctgagc acatgtggaa gccactggc agttttgtt ttgtgtttt
 tttgtttttt gagacacagt ctcgcctgtt caccaggctt ggagtgttagt ggcatgatct
 cagctcactg caacccctgc ctcccagggtt ccagcgattc tcctgcctca gcaccccaag
 tagctgagat tacagggtgtg caccaccttgc cctggctaat tttgtatgt ttgttagaga
 20 cggggtttca ccattttggc caggctggc tcgaactcct gacctcagggtt gatccggcc
 cctcgccctc ccaaagagct gggattacag gcatgagcc ccaccacacc cagcctgatt
 tacatttttta caagcaccct ggctaccacg tggaaacgtgg tctggcaag agagagggag
 ggaggccac gtggggctg ttgttttcat ccggcgacat aggagggtgg cttgaaccca
 ggcggtcga gtggggatgg agggatgtt aatatcttgg gatgtggaaat tctgagactg
 agccagcaga atctggcaac gaggaaacagg agggagagga agaagcacgg ctggcttccg
 25 tgtattttgtc ctgaacaact ggggttttgc ccacgtctt ctctgagttt tggagaggg
 aaagagaaac aggccgggtg taggcagggg agcatctgac attttgcctt agccacgatg
 agttggagat gcccgggaga tgccttgcgca gggaggccag ggaggactct ggagctcaga
 ggagagggtca gggctggagg ttaaaatgaa ggcatctgtca gcaaacagggt gtattnaaag
 ccatgggact agatggatc atccaaaaaaat ctggcatgtt tggaggagct ggagggccca
 30 ggacaaaaaac cctgggcgtc gatcctact agtcagattc acgcacagctt ccactgttt
 gatgctaact accaatcagg tgctgatgtt aaccatgtac acaccttcc tggaaatgccc
 accacaaggg actcttggca ccattttgtca aatggggaaa ctgagggtca gggaaatagc
 aagtgcacat cccctgggtt gttccctgtt ccccaaggag accttggatg actctcacca
 ccatcattca ttccattgtat gtacatttgc taagagcacc tgctaagtgc cacattcgag
 35 ttgggcagtg gagattcagc aatggatggg acacacagt catccctgccc tctgggagca
 caaggacaga aagggtcaga caagcaaaatg gagggtggg catgggtggcgtt caccctgtt
 atcccagcac ttggggaggc cgagggtggg ggattacctg agttcgagac cagcttggcc
 aacatggctc aaccctgtct ctactgaaaaa tacaaaaat tagccaggcg tgggtgtggg
 ctctgttaat tccagcaact tggggggctt aggaggaga attgcttgaat cgtggggaggc
 40 ggagggttgcgt gtagccgcac atcgccac tgcactccat cctgaaccac agagcgagac
 tctgtctaaa aaaaaaaaaa ggaaagaaag aagcagcaaa ttgggcttgc cgtgggtggc
 catgcctgtt atcccagcac ttggggaggc cgagggtggg gatcactcg agcccaggag
 tacaatggctc cagtttgcgt tgatctacat aacaccactg cagatccagc ctgggtgaca
 gagcggagacc ctgtctcaaa aaaacaaaca aacaaaagaa gcaaccctt caaaacccca
 45 tataatttaca aattatgtaa gaaaagaata cgggtacca ttttagatgg aggagggtca
 ggaaggactt tctaatttgcg taaaatccaa gcgaggcat gaagatgggaa aaggaatgt
 tcaggcgaga gggaaaggctg tgataacacc cctgagggtga gaaccgttctt gatattctc
 agaaaataaa atttccctt cactgggggg cagaagggtgc tgggagataa ggttggaaag
 tgactacacg cagatcacac aggggtctca gtggcaagggt gaggagccca ggctttattt
 50 ttaggacaaat gggggaggcat ggggtgtatgc tgaccaagggt agtactctc tgggtcagg
 atatgtatca aacaccatc ctgtgcaggc tgctgatcaat cgcactggag atactatatc
 tgaatagaac aaaaatcccc atcttgcacat ccttagagctg cactgttataa tatggtagcc
 atcagccaca tatacgaaat tacattttttttaatgaaat ggaaaatcca caagccacat
 ttcaagtttact cagcaggccac ctgttagtttgggttttttcc agccacccctt ggacagtgca
 55 gatcgagatc atggcatcgat agcatttttttgcggacaggcatt gctctgcagg gaggagaaat
 aacacaatgtt gtaaatattt aacaataat atatagcagg tcggatgtt gatgttagtt
 ctctgggtggc acagaaagca gggggaggag ataggaattt cctactaaca ggttatttgc
 ttttaatttttgc gcaactaagg aaggctttcc tggaggccca cattttaaagg aagtggggaa
 gtgagctatg cagatacttgc gaggacagac ttgtggcag gggaaacagc agtgcaaaagg

ccctgagggt ggaagatcac tattgtgttc aaggcaagac agggaaagcca gcgtttggct
 ggagcagagg gagagaaggg gagagtggga ggagaagatg tctgtgagat gatggggcag
 tgcttgcagaag gcctgtgtg ccacgtttag aacttggct ttgattctga gtgagatggg
 agtcatagga ggggctgagc agaggagca caggaccaac ttacattgtt aaaatatctc
 5 tggttgcattt gtggaggatg gactgtggg gaccagagac agagcagggg gcccagttag
 gaggctactg ctctagtta ggttaggaatg gaaaaggcag ctc当地accacaa gatggtagcc
 gtgggaaagg tgagatgtgg ccagattctg gatatgcttc agagaggcaaa aagaattct
 ggacagctt gatgttagggc atgaaataaa gagagtgaag aatagcccc aagattattc
 tgaaaggatg gaattgcccatttacccagct ggggaagact gtgggaggag caggccagc
 10 attcatgact tcccagccct ctctgaagcc tcaactgcag cccaaaggct ccaggtaga
 cccagccctc ttccatccca ggaatcttc ggttccctg gggaaagcata accttcggca
 aaggagatg tcccaggagc agagttctgt ttccgggtt gtgatccacc ctgactatga
 tgccgcccagc catgaccagg acatcatgtt ttgcgcctg gcacgcccag ccaaactctc
 tgaactcatc cagccccctc ccctggagag ggactgctca gccaacacca ccagctgcca
 15 catcctgggc tggggcaaga cagcagatgg tcagtagtgg gaggctggg gggagcaggc
 tactggctac ttggggaaatg gtgc当地aaagg atggggagtg ggaaaatgg tgaggggcca
 tgggaaatgat ggctaatggat gaggaccaat gggacagggt ttcaatgggaa gaaaggtcaa
 gggggagggg gagtgaattt gggagctggg ccagttagtgg aacagccaaat ggaaaatgt
 20 gaccaatggg tgaatagcat gggagagatg gaacataaga tgaaggttca ataaagaggg
 aaggtcagt gggagatgtc aatcaggaag gatgtcaaag gtcaaaagggg actgatcagg
 attcattgaa cagcaggaag gaataatggg gaaggaactg atggaaagaag agaaaccaat
 aaagcacaaa agccaaactga aggtgtgaa ttgagacagt gaatgggggt atagctgatg
 gaagaggggac taaggggaaa ggtatcaatgg tccagaggag tcactagagg aaaaacagg
 tccaatagat cagcaggatc catgaagtg ggc当地gtgtg tgaagggcca ataaagaaagg
 25 tgaaccattt gatgaaggc tagtgggaaatg gcagagacaa tggggagga tgccgcaagt
 tagaaaaggc ccaatgaggg cagtgggggaa tggtagggcc agtttagaaaa ggaccaagga ggtaatagg aaggagagc
 gagagagccaa atggggaggc gcaggccag ttagggaaagg accaatgagg aaggttagacc
 attggggggaa gggccaaatag aaaggggagga tccatgaggg aggtggggaa cagttagaaa
 30 aggaccaatg atgggggtgg accattggat gaagaaccaa tagaaaggaa gaaccaatgg
 gagagggcat ggc当地gttag gaaaagacca atgtcacag agtgc当地aaat caagatgaat
 caatggccag gaagtgtcca atgaagaatg gactactgt caggagggtt acatgagg
 agggcgtaac agaggaaagag ttctccaggta caactgaaac tactgaaagaa ggtgggacca
 gtggaaagaga gaaaagttggg ggagggaccc aagagaaaag gaaaaccaat agggaaatgag
 35 gactccttggaa agagagacta ttaatgagga agacagccaa tggggggaa gaatgataga
 aagagggacc aattaggagg caggagcat ggtatgaga tgtaagaatg agagacaaac
 aggaagaggg gtgc当地aaatg aaaagaggga ccaatagagg atggaggact tataggggtt
 ggggggtgac tggggaggat gagggggatg caaggccctg gctgagttctg gccc当地ctc
 40 ccccttaacag gtgatccccc tgacaccatc cagttgtcat acatccacc ggtgtccct
 gaggagtgtg agcatgcata ccctggccag atcaccaggat acatgttgg tgc当地gggat
 gagaagtacg ggaaggatc ctgcccagg aggtgaccgg gatctgc当地c ttacacagcc
 agggacagga cgaagtcaca aaaacatggc cagacacagg aagagagaga cacaggccaa
 aagagagctt tacagagaca gatagagaca ggctgaggga gaacccaaatg cttgaaaaga
 agagacttag ttcaacacac agagacacag tcaggatgat gcagagatat aaagacacag
 45 ccagcagaga caggaagtg agagacaagg atggaggccg cgggatcaag aaccagagag
 gccaggagca gggctcatg cctgtatcc cggcacttgg ggaggccaa gcaggaggat
 caccttaggtt caggagttcg agaccaggct gatcaacatg gtgaaaccct atctctacta
 aaaatataaaa aatttagatg ggc当地gtgg ctc当地gtctg taatccctgc accttgggag
 gccc当地ggcagg gaggatcacc tgggggtcagg agttcgagac cagcctgatc aacatgttga
 50 aaccctatet ctactaaaaaa tacaatggat aggtggca cagttgtca tgctgtat
 cccagcacct tggggaggccg aagcaggagg atcacctggg gtcaagagat tgagaccagc
 ctggccgata tggtaaaacc ctatctctac taaaatataaaaatgctt gggctgggt
 caggccctgt tagtcccagg tactcaggag gctgtggcag gagaatctact tgaacccctg
 ggc当地gggagggtt gttcgactgta gtc当地gtatc tgctactgtc
 55 aagattccgt ctcaaaaaaa aaccaaaaaaa caaaaattac gcaagcatgg tgggacacac
 ctgttagtccc agctactcg gaggctgagg ctggagaatt gcttaaacc agggaggaga
 ggctgc当地gtg agctgagatc acgccc当地gtc actccagctt ggggacagag ccagactctg
 tctaaaaaca aaaagaacca aagagaagta gtaaggaagc agatgttgg agggactgt

ccttcctcaa acagagcccc cacgagtcct gctcagaaac gaccaggctc tggaggaggg
 agacactagc tggggaaagg ggactccctc ccgaataactt taacttgggt ttctccatt
 5 gtcatccatc caggctctcc tctttatgcc agaatgacta atgcactgag ggatgtcag
 agaccaacca agggggagac acaggcagaa acggagacac aggcagaaac agggacagag
 acaggaaag cgatacatag caagttggac gcaaagaaag ggcaggtggg cgagactgtc
 10 ctcaagacac gaggtggaga ggtgtccctg gacagaatag tgccaggcat atctctccct
 gggccctccc tacctctccc acctgggtct tattgtctcc tcctccccc cctccctctc
 ctctctitcc tcctccctct cctccctcat catcttcttc ttttctctct ctctccatcg
 gtctctacac ctctgcctct ctccacaccc ctcaacttcc attcttaat ttttctctt
 15 tcttgcctc tatgttcctc tgcatcttg cattcatac tctgtgtt tgagtctctt
 ttattcttc tctaccatc tctctgtgt ctttgggtt tctactgtc tctctctctg
 tctctgttc cctgagtctt tctctccatc tttcgttacg tacctctgtc ctttcttacc
 tctctctgtc tacacacac acacacacac acacacacac acacacagtc
 tctgggtttc tatctgtatc tgactttctc ccttttctt gcagggtat tctgggggtc
 20 cgctggatag tggagaccac ctccgagggc ttgtgtcatg ggttaacatc ccctgtggat
 caaaggagaa gccaggagtc tacaccaacg tctcagata cacaacttgg atccaaaaaaa
 ccattcaggc caagtgtacc tgacatgtga catctaccc cccacctacc accccactgg
 ctgggtccag aacgtctctc acctagaccc tgcctccct cctctctgc ccagctctga
 ccctgtatgtc taataaacgc agcgacgtga gggcctgtat tctcccttggg tttacccctag
 25 cacacctatg acatacatgg aatagcacct gggccaccat gcaactcaata aagaatgaat
 ttt

30 SEQ ID NO. 7

KLK6 nucleic acid

CDS 246..980

35 aggcggacaa agcccgattt ttcctggcc ctttccccat cgccctggg cctgtcccc
 agcccggggc aggggggggg gccagtgtgg tgacacacgc ttttttttttcc
 gctggctcgc tcttcctgg ggacacagag gtcggcaggc agcacacaga gggacctacg
 ggcagctgtt ctttttttttcc actcaagaat ccccgaggc ccggaggccct gcagcaggag
 40 cggccatgaa gaagctgtatc gtgggtgtga gtctgttgc tgcagctgg gcagaggagc
 agaataatgtt ggtgtatggc ggaccctgcg acaagacatc tcacccatc caagctgccc
 tctacaccc tggccacttgc ctctgtgtt gggccttccat ccatccactg tgggtctca
 cagctgccc ctgcaaaaaaa ccgaatcttcc aggttttccat ggggaagcat aacccctggc
 aaaggggagag ttcccaggag caggttcttgc ttgtccgggc ttttttttttcc
 atgccgcccag ccatgaccag gacatcatgc ttttgcgcctt ggcacgccca gccaaactct
 45 ctgaactcat ccagccccctt cccctggaga gggactgctc agccaaacacc accagctgcc
 acatccctggg ctggggcaag acagcagatg gtgatttccat tgacaccatc cagtgcat
 acatccaccc tgggtccctgtt gaggagtgtg agcatgcctt ccctggccag atcaccctaga
 acatgttgc tgcctggggat gagaagtacg ggaaggattt cttttttttttcc
 gtccgctgtt atgtggagac caccctccatc gcttgcgttgc atggggtaac atccctgt
 50 gatcaaagga gaagccagga gtctacacca acgtctgcgat atacacgaac tggatccaaa
 aaaccattca ggccaaatgtt ccctgacatg tgacatctac ctcccgaccc accacccac
 tggctgggtt cagaacgtct ctcacccatc ctttgcctcc ctttctctcc tgcccgatct
 tgaccctgtat gcttaataaa cggcggcgcg tgagggtctt gattctccctt ggttttaccc
 55 cagctccatc ttgtcatc tggggaggac gtgtatgttgg aggacttggg tcctcggtt
 tacccttacc actaagagaa tacagaaaa tcccttcttgc ttttttttttcc
 ttccacacgt ttgttttccat cttgtcaggcc cccagccacg ttttttttttcc
 ctgtttacttgc tgggtgtccc ctttttttttcc actgtcaggatt ttttttttttcc

aagatgaaga taaggatgat acagtctcca tcagggcagt gctgttgaa agatcca
tttcacacct atgacataca tggatagca cctggccgc catgcactca ataaagaatg
tatttt

5

SEQ ID NO. 8

Hk10 amino acid

10 MRAPHHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLD
PEAYGAPCARGSQPWQSVLFNGLSFHAGVLVDQSWVLTAHCGNPKLWARVGDDHLL
LLQGEQLRRRTTRSVVHPKYHQGSGPILPRTDEHDLMLLKLARPVVPGPRVRALQLPY
RCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVTNNMICAGL
DRGQDPCQSDSGGPIVCDETLQGILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN

15

SEQ ID NO. 9

KLK10 nucleic acid

Gene 1...1580

CDS 220...1050

20

catcctgcca ccccttagcct tgctgggac gtgaaccctc tccccgcgcc tgggaaggct
tcttggcacc gggacccgga gaatccccac ggaagccagt tccaaaaggg ataaaaagg
ggcgttcgg gcactgggag aaggctgtat tccaggccc ctcccagagc aggaatctgg
25 gaccaggag tgccagccctc acccacgcag atcctggcca tgagagctcc gcacccac
ctctccgccc cctctggcgc ccgggctctg gcgaagctgc tgccgctgct gatggcgaa
ctctgggccc cagaggcgcc gctgctcccc caaaaacgaca cgcgcggc ccccaaggg
tatggctccc cgtgcgcgcg cggctcgcag ccctggcagg ttcgcctt caacggcc
30 tcgttccact gcgccgggtgt cctggtgac cagagtggg tgctgacggc cgcgcactgc
ggaaacaagc cactgtgggc tcgagtaggg gatgaccacc tgctgctt tcagggagag
cagctccgccc ggaccactcg ctctgttgc catcccaagt accaccaggc ctcaggcccc
atcctgccaa ggcgaacggc tgagcacat ctcatgttgc tgaagctggc cagggccgt
gtgctggggc cccgcgtccg ggcctgcag cttccctacc gctgtgcctca gcccggagac
cagtgcagg ttgctggctg gggcaccacg gcccggcggg gagtgaagta caacaagg
35 ctgacactgct ccagcatcac tattcctgagc cctaaagagt gtgaggctt ctaccctgg
gtggtcacca acaacatgtat atgtgttgc ctggaccggg gccaggaccc ttgccagagt
gactctggag gccccctggt ctgtgcacgag accctccaag gcatccctctc gtgggtgtt
tacccctgtg gctctgccc gcatccagct gtctacaccc agatctgaa atacatgtcc
40 tggatcaata aagtcatcgt ctccaaactgt tccagatgt acgctccacg tgatccagat
gttatgctcc tgctgatcca gatgcccaga ggctccatcg tccatccctc tcctccccag
tcggctgaac tctcccttg tctgcactgt tcaaaccctc gccgcctcc acacctctaa
acatctcccc tctcacctca ttccccccacc tattcccatt ctctgcctgt actgaagctg
aaatgcagga agtggtgcc aaggtttatt ccagagaagg caggaaggcc gtcacaccc
45 agcctctgag agcagttact ggggtcaccc aacctgactt cctctgcac tccctgtgt
gtgactttgg gcaagccaag tgccctctc gaacctcagt ttccctcatct gaaaaatggg
aacaatgacg tgcctacctc ttagacatgt tggaggaga ctatgatata acatgtgtat
gtaaatcttc atggatgtt tcatgttaagg cttaacacag tgggtggta gttctgacta
aaggttaccc gttgtcgtga

50

SEQ ID NO. 10

KLK10 nucleic acid

Gene 1..5574

mRNA join(48..120, 605..701, 2455..2635, 3589..3863, 4195..4328, 4793..5474)

55

CDS join(614..701, 2455..2635, 3589..3863, 4195..4328, 4793..4945)

Promoter 1...47
 5'UTR join(48..120,605..613)
 exon 48...120
 exon 605...701

5 ttggggtcaa aaggaaaggt cccgccagggt gtcctgggc agaggatacc agccggcagac
 cacaggcagg gcagaggcac gtctgggtcc cctccctct tcctatcggc gactcccagg
 tgaagctacc tgcacccac ccgggttggg gtggatttgcg agaggatggg tggaaacccc
 cgggcccacag gcaggagccg gcttagagcc tcggtttctc cactgcggga cgccgaagtc
 10 ccccccgtgt gaggttggaa aagaggctcc cactggctcc gaggctcgga tccccacccc
 gcgcgtgaag gaggggaaa cctcgggcgc ggcgtggctg cagccagggt agctggggcgc
 cggagagccgc tccatcggg cacagggagg acggaaat gccgcgagggg gcgtcattag
 ggttattgtt cccattaccg tggccatggc cgaatctcc tcctggccagc ccctgggggtt
 atcggctgca ggtcaaaagg gtgcgttgcgg gctgggggtt cccaggctgg gcggatgagc
 15 gcggcgaggt gggggctctt aacggagcat ctgttttaac cccggccctgc acacacccca
 gcagatctg gccatgagag ctccgcaccc ccacctctcc gccgcctctg gcggccgggc
 tctggcgaag ctgctggccgc tgctgtatggc gcaactctgg ggtttaggtt gggacaggggg
 gcgccccggat ggcgcgggtt gaggcacggg cggggggca atgtgttccc gtacaccaagc
 cccgcgcacc tctccctcccc cgagacccca gcacccaccc agcgcctcgg agcacggccc
 20 gcccccaagt cagctggcc ctctttctgg ctggggccct gggtgaccgg ccccaactcag
 gcccgtccg atttctgcca cccggatctt cgctcttccg tggactcttcc ggctgtttct
 ttctccctctt cttacgcgc cccatcccg cccgcctcca ttttacacta ccgtgttttt
 ttttatttttggt ttgttttttggt gagacggagt ctgcgtctgt cgcccaagggtt ggagtgcagt
 ggcgcgatct cggctactg caagctccgc ctccgggtt cacaccattt tcctgcctca
 25 gcctcccgag tagctggac tacaggcgc cgcaccaag cccggctagt tttttgtatt
 ttttagtagag atgggatttc accgtgttctt cgatctctgt gcctcggtat ccgcctgcct
 cggccctccca aagtgtctggg attacaagcg tgagccaccc cttccggccca caccacagtg
 ttttattctg agtcttgcct taccgtttt tgccctctcc cctcaacttt ttcttccttc
 ttcccttttc tctcttcttt ttctttcttt ttcttccttc ttcttccttc ttcttccttc
 30 tccttccttc ctcccttc ttcccttcgt ttgtttcttc ttcttttttctt ttttttttctt
 ctatttttt ctctttttt ctctttttt ttctttttt ttctttttt ttctttttt ttctttttt
 tttttttttt ttttttttggat acagggcagt gctgtgtctc cgtggcttggat tttttttttt
 ccaatcagag ctcaactgcgc ctcgcaccc ctgggctcaa gctgtgttggat tttttttttt
 tagctggatcacaggcatg caccaccaca tccggctttt tttttttttt tttttttttt
 35 ttttttttggat acagggtctc actctgtcgcc ctagactggat gtcgtgttggat tttttttttt
 ctcatgtcaa cctccaccc cttggctcaa gcgatctcc cacctcagcc tcccaaggat
 ctgtgactac aggcgcatgc ctccgcaccc ctgggctcaa acttttttttggat tttttttttt
 tttttttttggat actgggtctt gctgtgttgc cccggcttggat ttttttttttggat
 40 cggtccaaacc gcctggctt cccaaatgtc tgggattaca ggcgtaaacc actgcggccc
 accccctctcc tgggtttcaa tcccggtttt ttatttcacac cccttccttc ccccgatcccc
 cgagttctat ccccgaccc ttacctcccc gccgcgttca atccccggcc ctatctcgac
 cagcgcacgtt cttagccagct ctccaggccgc gtcgcgttca gtccttccttc tccagacccca
 ccctattctg tctcattact ccacgttacc ctatcccagc ttcccttcac ttccacgcgc
 ttcttccttc cccatttcctt cgggtgcaccc gaaacccca atatttcctt accaccctcg
 45 cgttctggct gcgtccccccg tcccccgaacg cagtccaggat ccacagccca gtcaccaaccc
 caaaccggaga ccctccctc cgtgttttgc ttccgtttcc ttttttttttcc ccaagccgcag
 aggccggcgct gtcctcccaaa aacgacacgc gcttggaccc cgaaggctat ggcggccccc
 ggcgcgcgcgg ctgcagccgc tggcagggtct cgtctttca cggccttcgc ttccactgc
 cgggtgtctt ggtggaccag agttgggtgc tgacggccgc gcactgcggaa aacaagttag
 50 aggagatcca tccccggaga cggccacccggg ggctgtggag gccggcttcca gggaggagcg
 ggcaggggcg ggttcttcgg aactccccaca gcttggggat cgggtcccccgg tgccttttcca
 gcaggaggag agaccgggtt tgcgtgttgc cccggggat cgggtgtggat cctttccgc
 atttctgggc ccgtcactcc tctccctgtt atttcttcgg agctcttagga ggaggtggat
 gcctgcacac gatagaagcc agggtccggt gtggtcaggat attttagaaact aaaggaaaaag
 55 gttcacttcg tgagtcccg ttgaaggagg aagggttggg tattaccaca gaaaaaatgt
 ggagttgggc tgggtctcggt ggctcaccc gtaatccca gcacttttttggggaggccaaaggc
 ggggtggatca cctgaggtca ggagttcaag accagccctgg ccaacatggt gaaaccactt
 ctcaactaaa aataaaaataa aataaaaaat aaaaaat tttt aaaaaat tttt aaaaaat
 aaggctgggt gtggtggccggtt gtcctgttcc tcccaatgttcc tcccaatgttcc tcccaatgttcc

ggagaactgc ttgaacctgg gaggtggagg ttgcagttag ccgagattgc gccattgcat
 tctagcctgg gtgacaagag cggaaactctg ttcaacaaa gaaaagaaaa agagaaaaaga
 aaatgtggaa ggcttaccta ggtgtccagg ccccccagccc tcctcaattc ctgcagatcc
 tcagagctca aacaactgtat tcctccttcc catgtccact gaggtccctc tctccacaa
 5 ggcctcttc cctcagactc ttcttatctc cagggccctgc ttcaactgccc acctgcttc
 ccagtcctcg tgaagggtt gccttacat gccttccct tccccccaggc cactgtggc
 tcgagtaggg gatgaccacc tgctgttct tcagggcagc gagtcggcc ggacgactcg
 ctctgttgc catcccaagt accaccaggc ctcaggcccc atccctgcca ggcgaacgga
 tgagcacat ctcatgttgc taaagcttgc cagggccgtt gtgcggggc cccgcgtccg
 10 ggcctgcag ctcccttacc gctgtgtca gcccggagac cagtgccagg ttgtggctg
 gggcaccacg gcccgggaa gaggcaagag ctggggctct gaggccagaa cctcaggagg
 agggggctga gggcctgaac ccctgggtct gaggaaaggat gggctggga ctgattcc
 ggatctgagg gaggacggc tggggtctt gatgccttgg tctgtgagtc tgaggggagg
 15 aggggctggg ggcctggact cctgggtctt agtggggagg ggctggggc aggattctt
 agtctgaagg aggaggggctt ggggtttagt atagaaacgg tcttgcatact ggactccttg
 ctcccaagg attggggctt ggacccaggg attactggca tatttcctt tcagtgaagt
 acaacaaggc cctgacctgc tccagcatca ctatccttag ccctaaagag tggaggtct
 tctaccctgg cgtggtcacc aacaacatga tatgtgttgc actggaccgg ggcaggacc
 20 cttgccaggt agggtcttgc cagggagat ctctgactcc tgggaggagg gacaggagg
 ttatggaaa agagcagacc ctgtggccga tcccaaactc cattcccaaa cccatcctt
 accccaaactc ttacccagac ctaacccctt cctcatccct atccctcaatc ccatttccat
 cctaaccctt cccattttcc atctccaagc ccattttcat cccctcacct tccatgaact
 acaatccaa cccaagtctc actgtgcctt cattctcatc cccagccca acctcccata
 25 acctgaagtc cacccattt cctacccctt agtcatacc taattccaa cccatccat
 cctcgctt atcccaaccc aacccttcc ttccccacca ctgccccaga tccaaagt
 acagctctca cggtggcaca ttatattgt ctctcctt tgccacccccc agagtgactc
 tggaggcccc ctggctgtt acgagaccc ccaaggcatc ctctcggtt gtgtttaccc
 ctgtggctct gcccagcatc cagctgttca caccctagatc tgcaaataca tggctggat
 30 caataaagtc atacgttca actgtatccag atgtatccgt ccagctgatc cagatgttat
 gctccctgtt atccagatgc ccagaggctc catgtccat cctcttcctc cccagtcggc
 tgaactctcc cctgtctgc actgttcaaa cctctggc cctccacacc tctaaacatc
 tccctctca cctcattttcc ccacccatcc ccatttctgt cctgtactga agctgaaatg
 cagggatgg tggaaaaggat ttatcccaaa gaagccagga agccggcatc caccctgg
 35 ctggagggcag ttactgggtt cacccttacc gacttccctt gccactcccc gctgtgtgac
 tttgggcaag ccaagtgc cctctgaacc tcagtttctt catctgaaa atggaaacaa
 tgacgtgcctt acctttttaga catgtgttga ggagactatg atataacatg tggatgtaaa
 tcttcatgtt atgttcatgt aaggcttac acagtgggtt gtgagttctg actaaagggtt
 acctgttgc gtatctgac cacgtcccg tggaaagcgtt tggccaggaa agaagtgcac
 40 agggtagccc ccaatccaa cttccatcc ccaacccttta gggatgttgg aaga

SEQ ID NO. 11

Hk11 amino acid

45 MQRLRWLRDWKSSGRGLTAAKEPGARSSPLQAMRILQLILLALA
 TGLVGGETRIIKGFECKPHSQWPQAALFEKTRIV
 HLQHNLQKEEGCEQTRTATESFPHPGFNNSLPNKDHRRNDIMLVKMASPVSITWAVRP
 LTLSSRCVTAGTSCLISGWGSTSSPQLRLPHTLRCANITIIIEHQKCEAYPGNITDTM
 VCASVQEGGKDSCQGDGGPLVCNQSLQGIISWGQDPCAIRKPGVYTKVCKYVDWIQ ETMKNN

50

SEQ ID NO. 12

Hk11 amino acid

55 MRILQLILLALATGLVGGETRIIKGFECKPHSQWPQAALFEKTR
 LLCGATLIAPRWLLTAAHCLKPRYIVHLQHNLQKEEGCEQTRTATESFPHPGFNNSL
 PNKDHRRNDIMLVKMASPVSITWAVRPLTSSRCVTAGTSCLISGWGSTSSPQLRLPHT

LRCANITIEHQKCEA^NPGNITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQGIIS
WGODPCA^ITRKPGVYTKVCKYVDWIOETMKNN

5 SEQ ID NO. 13

KLK11 nucleic acid

10	aggaatctgc	gctcgggttc	cgcagatgca	gagggtgagg	tggctgcggg	actggaagtc	61
	atcgggcaga	ggtctcacag	cagccaagg	acctggggcc	cgctcctccc	ccctccaggc	121
	catgaggatt	ctgcagttaa	tcctgcttc	tctggcaaca	gggctttag	ggggagagac	181
	caggatcatc	aagggttcg	agtgcagcc	tcactccag	ccctggcagg	cagccctgtt	241
	cgagaagacg	cggctactct	gtggggcgcac	gctcatcgcc	cccagatg	tcctgacagc	301
	agcccactgc	ctcaagcccc	gctacatagt	tcacctgggg	cagcacaacc	tccagaagga	361
	ggagggctgt	gagcagaccc	ggacagccac	tgagtccttc	ccccaccccg	gcttcaacaa	421
	cagcctcccc	aacaagacc	accgcaatga	catcatgctg	gtgaagatgg	catcgccagt	481
15	ctccatcacc	tgggcgtgtc	gacccttcac	cctctcttca	cgctgtgtca	ctgctggcac	541
	cagctgcctc	atttccggct	ggggcagcac	gtccagcccc	cagttacgccc	tgcctcacac	601
	cttgcgtatgc	gccaacatca	ccatcattga	gcaccagaag	tgtgagaacg	cctaccccccgg	661
	caacatcaca	gacaccatgg	tgtgtggccag	cgtgcaggaa	ggggggcaagg	actctgcca	721
	gggtgactcc	ggggggccctc	ttggctgttaa	ccagtcattt	caaggcatta	tctctgggg	781
20	ccaggatccg	tgtgcgtatca	cccgaaagcc	ttggttctac	acgaaatgt	gcaaataatgt	841
	ggactggatc	caggagacga	tgaagaacaa	ttagactgga	cccacccacc	acagcccatc	901
	accctccatt	tccacttggt	gtttggttcc	tgttcaactct	gttaataaga	aaccctaagc	961
	caagaccctc	tgcaaacatt	cttggggct	cctggactac	aggagatgt	gtcaacttaat	1021
25	aatcaacctg	gggttcgaaa	tcagtgagac	ctggattcaa	attctgcctt	gaaatattgt	1081
	gactctggga	atgacaacac	ctggtttgg	ctctgttgc	tccccagccc	caaagacagc	1141
	toctggccat	atatcaaggt	ttcaataaaat	atttgctaaa	tgagtg		

SEQ ID NO. 14

KLK11 nucleic acid

```
30 gene 2313..7622
mRNA join(2313..2398,4189..4263,5061..5217,5545..5810,
6627..6763,7158..7622)
35 CDS join(4224..4263,5061..5217,5545..5810,6627..6763, 7158..7310)
```

40	tgataaatgt	gttctctctc	ctcattggtc	agggccccag	ccattgtcct	tgagagaatg	61
	ctcgactctt	tatgttgtct	tgacagcctc	ccctgagatt	ggtcattaaat	gactgtgctc	121
	tctctcctca	ttggtcaggg	ccccagccat	tgtccttgag	agaacctctg	tcctttatgg	181
	agttccaccc	ttcttccctg	ggattggccc	ctagagacag	tggttcttct	cttttggta	241
	gocattgcca	ttgtcctccg	ggaaagtgtat	tatactcttt	tgtctaataatg	ccagacttgg	301
45	agccctcccc	aaggcccagg	actgggttga	agggttgggg	aggaaaacag	aaataagatg	361
	tctcccttgt	tcagacagta	cttctcttcc	cttccagggt	gattctgggg	gccccctggt	421
	gtgtggggga	gtccttcaag	gtctgggtgc	ctgggggtct	gtggggccct	gtggacaaga	481
	tggcatccct	ggagttctaca	cctatatttt	caagtatgt	gactggatcc	ggatgatcat	541
	gaggaacaaac	tgacctgttt	cctccaccc	caccccccacc	ccttaactt	gttacccctc	601
50	tggccctca	agcaccaata	tctccctccat	cacttccct	agctccactc	ttgttggcc	661
	ggaaacttct	tggaaacttta	actcctgcca	gcccttctaa	gaccacacg	cggggtgaga	721
	gaagtgtgca	atagtctgga	ataaaatataa	atgaaggagg	ggccatgtt	gtccatttga	781
	agtccctcatg	ctgggtgaga	ctggaagaag	gactcagcag	tttccctatc	tcataggat	841
	agaaaacagag	ctcaaataag	gccaggcaca	gtggctcaca	cctgttaatcc	catcatttg	901
55	ggaagctgag	gcaggtggat	cacctgaggt	caggaactcgt	ggaccagcct	ggtcaacata	961
	gtgaaaacccc	aactctacta	aaaaatgcaaa	aattagccag	gcatggtggc	gcatgcctgt	1021
	aatccccagct	actcaggagg	ctgagacagg	agaatagcat	gaacccgtga	ggcagaggct	1081
	gcagcgagcc	gagattgaac	cattacactc	cagcctggc	gacagaaqca	qactccatct	1141

	caaaaaacaaa	caaacaaaaa	acccagtgc	caaataggat	gagggtcttc	cctgagtagt	1201
	tactcagaaa	tggagtagaa	aaagttactt	ttaataat	aggccgggt	cagtggccca	1261
	cgcctgtaat	cccagcactt	tgggagggcg	aggtgggagg	atggctttag	ctcagatttc	1321
5	gagatcagcc	tggcaacaca	gtgaaatctt	gtcactacaa	aaacacaaaaa	aattagctgg	1381
	gtgtgggtgt	gcgtgcctgt	agtcccagct	acttgggaa	ctgaggtgg	aggatcaccc	1441
	gagccgggga	ggtggaggct	gcaaagagcc	gagatcatgc	cactgcactc	cagcctggc	1501
	aataaaagtga	gaccgtgtct	caaaaaacaaa	aaccagcaa	tataaataag	acacatgttt	1561
	cttcatctgg	cataatagaa	atagtgc	gagcttataa	gctttcaag	agtccacaaa	1621
10	agacccgaaa	aagaaaaaaa	aaattgttag	ctccaaaata	ccagatgaaa	gctgcaaagt	1681
	caacatttat	gaccatttaa	tccaaatgtcc	ataaaaacgt	gcattcttc	cactagccaa	1741
	ctgcagttt	ctttcttgc	atgaagcata	cattgtatct	ttaatgtgg	acgtggctt	1801
	gttctaataa	gacgaagggt	ggagtgcagg	cttggaaagc	aggagagctc	agcttacgtc	1861
	tttaatcttc	ctgcccaccc	cttggattct	gtctccactg	ggactcaaga	ggtgaggaga	1921
15	gaccatctcc	ccaaatgcac	tgaaggaaaa	ctggaggagg	gagggagtga	gggtgatca	1981
	taccagcgga	ggcacat	ctgagccccc	ccgcagtctg	ctcttccaa	gtgaccctc	2041
	cttggaaaggct	gateccaacc	tccccctgaa	gcaggtctgt	caccccccac	tctcagatga	2101
	agaaaactgag	ccttgcaggg	gtggagtccc	ttgtccccac	gtcataagg	tagtcatagt	2161
	ataggaaga	ggaagcacct	aggtttgagg	ccagggtctgg	ctgctgtcag	aacctaggcc	2221
20	ctcccctgcc	ttgctccaca	cctggtcagg	ggagagaggg	gaggaaagcc	aagggaaagg	2281
	acctaactga	aaacaaacaa	gctggagaa	gcaggaatct	gcgcctgggt	tcccgagatg	2341
	cagaggttga	ggtggctgc	ggactgaa	tcatcgcc	gaggtctcac	agcagccagt	2401
	aagtgaacag	ctggactcgg	gctgcctgg	ccgcaggagg	aagcggccag	ggaaagggtc	2461
	agcagaggag	cgaggccca	gaggagccct	gggtggagc	acagccaagg	gctctgttcc	2521
25	ctttcctgga	ctcggttcc	acaggccctg	acgtgcctcc	cccacccctc	ggtctgtccc	2581
	ctgtgcctgg	cagcagccccc	acctgtgtga	catcccagca	caccccccct	ctccttgcaa	2641
	aggagaaggg	agcggcctag	gggaggccag	ggggccacct	gggctggggc	tgtggagagg	2701
	gagtggctgg	gacgggagga	aaaagagaga	cggagattag	atggaagaag	aggatttca	2761
	agacaaatttgc	ccagagatgc	agtcaagag	actgactgag	agacacaaaag	atagaaggaa	2821
30	ttagagaaag	ggccacacag	agccagacag	agagagaaga	gtggagatgg	agacagggac	2881
	gaggacagag	aaaggcagac	agacacatag	ggacagaaaag	aaaaaaatca	cacaaagtca	2941
	gaattactga	atgacaggaa	atgacacata	gaacgagaca	cagattcaga	gactcagggc	3001
	agggaaagga	aggctgcaga	cagacagaca	gacagaggga	ggctgagaca	cagggagaag	3061
35	aggggcttgg	agaggtggca	caggcagca	gccagtcct	cagaggcctc	cggggagggc	3121
	cctcacacac	accggccccc	ggggcataa	ggcagggtct	ggaggccagt	cattctgggc	3181
	ccgcccagg	ccggccccc	gccagccgc	ctggctgg	cctggcacct	gggcgtccaa	3241
	cccagcctac	ctgtgttagc	tgcccccact	gccgtctcc	ccgcaactgg	gccccagag	3301
	ccccagccccc	agagcctgt	agtccaggg	gaaaggaaag	ctggccctcc	cegtccagg	3361
40	gtcagccctc	cccaaggaca	cctgtccac	tcgggcaccc	atttctccct	ctgctctgtc	3421
	cttctctgt	tgggtgggg	ttcctggct	ctctctacac	ctctcac	cgatggctgt	3481
	ccgcagcctc	agttacctct	aatctccatg	gcttcagct	ctgagctggc	cctctgttcc	3541
	caccccccgt	ggccagggca	gcggagggca	ctggccctcc	cctcgacc	ccccggccag	3601
	ctttgcttgg	ctgtccttca	aaagggcagg	ggtttggcg	acagggcttc	agcaagccgg	3661
	gtgatgggg	tcccagacat	tgtctgggc	tgagccccct	actccctcc	agcagacac	3721
45	aaaggctcca	tatcgctcg	ctgcgaagac	aatgaaaaag	gggtggctac	gaaacgggt	3781
	ctggttcccc	ttgtccttcc	accccaagct	gctggggct	ggccagctc	caaggcaaga	3841
	aggaaaacat	cctctgacat	gtgccccgg	ggtcccatgg	ctgacttgaa	cagggccgaa	3901
	ccatggcttg	acagctcaa	gccccctcca	acgacttcca	catggttctt	ggtatctcg	3961
	aagcttctag	ctgtgaccag	gccccctcca	aggccaccct	agacacotaa	gatatatttt	4021
50	aagtgtttgg	agatctgagt	gtgtgagaa	acagggatt	tcccaac	tgtttctccc	4081
	aagtggggag	cgggagcagg	tgagggagag	aggagaggc	atgagcc	ccccccctcc	4141
	cgatttcccc	gtaaagtgt	gcggccccc	gtccctcc	gttcccagag	gaacctgggg	4201
	cccgctcc	ccccctccag	gcccgtgg	ttctgcagtt	aatcctgtt	gctctggcaa	4261
	caggtacca	ggggatgggg	gcagggcagg	atccctcc	ttgaatctct	ggatccccc	4321
55	aaccctctgt	gtctggacag	tgacagggt	gattccaaat	tacagaacaa	ccataaggc	4381
	acctgaactg	gagcagtgt	catggggcc	tggatgc	tctagataat	ccctttaat	4441
	gccaaaggag	gagaggtcaa	gggggtcgta	aagggtcccg	tggaggggct	gaggaagctg	4501
	gagttgggg	agcagtca	caaagcccc	aggacagggg	ctactgacca	accagtatgg	4561
	aagtattttc	ttttttttt	ttcccagaga	caaagtcttgc	ctctattgtc	caggctggag	4621
	tgccgtgg	ccaacacggc	tcactgc	cttgacttcc	cgggcttaag	tgatcctaa	4681

5 gccatctcag cttccccgt agctgggacc acaggcacct gccaccaagc caggctaatt 4741
 gtttaattgt ttgttagagat gggggaggag gtctcactat gtttgcctag gctgatctag 4801
 aactcctggg ctcaagtaat cctcccacct tagcctctca aagtgctggg attacaggca 4861
 tgagccactg catttgacct tatggaagta ttttcatcct ttaatacccg accccagcat 4921
 5 ccaggcAAC ccagaggAAC accagaccAG gcccAGACC acccACTCTC tttCTCTCT 4981
 ccccACCCCCC atttCTGGG gtcctcCTGG tctaccACCT ctcCTCCTG agcccTTCT 5041
 ttGCTCTCA cccCCTCCAG ggCTTGTAGG gggAGAGACC aggATCATCA agggGTTCGA 5101
 gtGCAAGCG cactCCAGC cctGGCAGGC agccCTGTC gagaAGACGC ggCTACTCTG 5161
 tggGGCGACG ctcatCGCC ccAGATGGCT cctGACAGCA gcccACTGCC tcaAGCCGTG 5221
 10 ggtGCGGGGG ctggGGCGGT gcccGGGGTGG gggGCTGGGA atGGGGAGAT ggATGGAGAG 5281
 aagCTCAGGG atAGGGGTGC tggtaAGGGG attAGAGATG gggATGGGTG gtGTCAGCAA 5341
 ggttGATGGG ctcGAGTTGG tattGAAGGT gggGGGATGA atGGGGTGG gatGGGGCTA 5401
 tggCTGGGAA gggGGCTCG gtggGAGAGC tggAAAGAGGT tggAAAGCAGA gcgATGTTTC 5461
 ttCATCCTCA aaggGTGTCAC tcacCTCTCC caccatGTC tccccGACC tttCTCTCTC 5521
 15 caactactgt ctctCCACC tcAGCCGCTA catAGTCAC ctggGGCAGC acaACCTCCA 5581
 gaaggAGGAG ggCTGTGAGC agACCCGAGC agCCACTGAG tccTTCCCCC accCCGGCTT 5641
 caacaACAGC ctccccAAACA aagACCACCG caatGACATC atGCTGGTGA agatGGCATE 5701
 gccAGTCTCC atCACCTGGG ctGTCGACc cctCACCCCTC tccTcacGCT gtGTCACTGC 5761
 tggcaccAGC tgcCTCATTt ccggCTGGGG cagcacGTC agccccAGT gtaggAGCAC 5821
 20 cagagGGGAA cctGGCAGGG ggtGGTgagg agggAGTGGT caggATTGtG gaaggGTTCA 5881
 gggcatcaga gatGCGGTtC acAGTgACGA tGtGGGATAA gttGAGAGGA tGtGtGAA 5941
 acgtCAGGAT agggGGGTGG ggacAAAAGT tggGGCCTTG gAGTCAGACG gacGGGATAT 6001
 gcaatcatac atccataacc tcctGGTTGT aagacCTTAG gcaAGCAGCT tcacCTCTCT 6061
 gaatcttGAT ttTCTTCTCT ataaaATGAG aatGATTATA cccacCTGTC aggATTGGAT 6121
 25 tagagataat gtatATCAAG caactGACAT aaATCATTa ttggatAGCA ggCTGGGAC 6181
 cgtGGCTCAC gcCTGTAAATC ccAGCACTT gggAGGGCCGA ggtGGGAAGA tcacCTGAGG 6241
 tcaggACTT gataCCAGCC tggCCAAcGT ggtGAAATCC catCTCTACT aaaaATGTGA 6301
 aaattAGTTG ggCGTGGTTG tGtGCGCCTG taatCCcAGC tactCggGAG gttGAGGcAG 6361
 gagaATCgCT taaACTGGG agACGGAGGT tGcAGTgAGC caAGATCAGC ccACTGCACT 6421
 30 ccAGCCTGGG caacAGAGCA agACTCTGTC tcGAAAaaaaaaa aaaaaaaaaa gctGGATAGC 6481
 attGtGTTG ctattGTTc aagaAGAGAG gtGAGTTGGC tGcGTCTAAAG gacAGGGATT 6541
 cccccAGGGG cggGATcaca gcaAGCACTG cattAGGGGA ggtGGCAGGG ggCTCATTC 6601
 cacAGCCCT cacGCTGTT ccacAGTAcG cctGCTCAC acCTGCGAT ggcCacaCAT 6661
 caccatCATT gagCACCAGA agtGTGAGAA cgcCTACCCCC ggcaACATCA cAGACACCAT 6721
 35 ggtGTGTGCC agCGTGCAGG aaggGGGCAA ggACTCCTGC caggCTAGT tggTCTCAA 6781
 ccacAGCCCC atccccATCC ccAGCTTCAA tgACATCTT accGACATCC acaATTTCAT 6841
 ccccaACCTC aaccCAGCCGA cccCTGCAc tccCAATCCa tctCTTCCCC tGtTCCGTT 6901
 tctGACCTCA gcacAAACTT cagCTCCATC cccGTTCCA caccATTTCC agCTCCAACC 6961
 atccccAAAC tcGTTTTGA gcCTAAACCC atCCCTTATC ccACCCATAA tccCAAGCTT 7021
 40 atCGCTAAAC ctatCACCTT tcccAGTgCC taccCATCCT gtCTCGGCC cactCTCAAG 7081
 caccGTCccc acCTCCTCCC tggCTAACAC catGCTCAAC gctttCTCTG accGACATC 7141
 tctCTCCCCG tgcccAGGGT gactCCGGG gcccTCTGGT ctGtaACCAG tctCTTCAAG 7201
 gcatttatCTC ctGGGGCCAG gatCCGTGTG cgatCACCCG aaAGCCTGGT gtCTACACGA 7261
 aagtCTGCAA atATGTGGAC tggATCCAGG agACGATGAA gaACAATTAG actGGACCCA 7321
 45 cccaccACAG cccatCACCC tccATTTCCA cttGGTGTtT ggTTCTGTt cactCTGTT 7381
 ataAGAAACC ctaAGCCAAG accCTCTACG aacATTCTT gggCCTCTG gactACAGGA 7441
 gatGCTGTCA cttAATAATC aacCTGGGT tcGAAATCAG tgAGACCTGG attCAAATTC 7501
 tgcCTTGAAA tattGTGACT ctGGGAATGA caACACCTGG tttGTTCTCT gtGtGtATCCC 7561
 50 cAGCCCCAAAG gacAGCTCTC gGCCATATAT caAGGTTCA atAAATATTt gctaATGAG 7621
 tgaatCTACT gAGTGTtAC tATGTGCTAG accCTGATCC aatGGCTTTt atTTTATTT 7681
 atTTTTGAC agAGTCTCGC tctGTCACCC aggCTGGAGT acAGTGGTGC tatCTCTGCT 7741
 cactGCAACC tccACCTCTT gggTTCAAGC aattTCCTG cctCAGCCtC ctGAAATAGCT 7801
 gggattACAG gtGCTTACCA ccACATCCGG ctaATTTTG tattTTTtAG tagAGATGGG 7861
 gcttCACCAT gttGGCCAGG ctGGTCTCGA actCTGACc tcAGATGATC tGccCTCCTT 7921
 55 ggCCTCCCCAAG actCCCTGGGA ttACAGACGT gagCCACCGC gcccGCCCCG ctTTCAATTa 7981
 ttaattaaaaaa gaaattaaaaat taattAAATCt atttagGAGA cAGTCTTGTCT ctGtGCCCCA 8041
 ggCTGGAGGT cAGTAACAAAT cacAGCTCAC ggCAATCTCA attTCCTGGG gtCAAGTGT 8101
 tGTCCTCCCT cAGCCTCCAG agTAGCTGGG actACAGGCA catGCCACGA agCCCAgCTA 8161
 atTTTTGAT ttttCGTAGA gacAGAGGTC tcAGTATGTT gccccGGCTA gtCTCAAACt 8221

5 cctgggctca agcagtctgt cctcctcagc ctccaaaagt ggtgagatta caggcatgag 8281
tcgctgtgcc tggcctccaa gcactttcaa atgtatcaac ttaatcctca caaaaaccctg 8341
tgaggtcggt actgtttca taccttattt atagttgaag aaacagacac agagaagcaa 8401
agtcaacttgc tcacagtac gttggcttagga gagcaaggat ctgaagcaag gcgatctctt 8461
aattaccaag tgatgttcct ggagtaaggc tctgtttgtt tccttcctg taaaatgctg 8521
catgcaaaag tataacacag taagtaaaga agtcagttag cctgcacata ctaagaccta 8581
accaaaggag cttattgtt ttctccaact tccatgatag gtaatttagat agtggagacc 8641
tctgctggcc aatatggtag ccactaaccg cagctggctc ttccaattaa aattacataa 8701
10 agccagaaaat gtaactcctc tgtctcactt gttatatctc caaggctgga tagccacatg 8761
tgactggtgg tggctggatt agctagtgcataataaacat cactgcagaa agttcagctg 8821
agcagcactg agttagatgg cctctgaaga ggatgtccca cggagagaat ccagaactca 8881
ggatctttt tttttttt ctttgcgaca gagtttgct ctgtcaccca ggctggagtg 8941
cagttggcgtg atctcggctc actgcaactt ctgcctccca ggttcaagca atttcctgc 9001
15 ctcagccccc ctagtagctg ggactacagg cctgtgccaa catccccagc taattttgt 9061
gtcttttag tagagatggg gtttcactat gttggccagg ctggctcga actcctgacc